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         The environmental pollutant, 6-nitrochrysene (6-NC) is the most potent carcinogen evaluated 
by the newborn mouse assay. The genotoxicity of 6-NC is derived from its ability to form 
electrophilic species in cells which can react with nucleophilic sites of 2'-deoxyguanosine (dG) 
and 2’-deoxyadenosine (dA) in DNA to generate DNA-carcinogen adducts. DNA lesions derived 
from 6-NC can play important roles in the development of human cancer by inducing mutations 
in crucial genes resulting in the disruption of gene expression. Mutations in an oncogene, a tumor-
suppressor gene such as p53, or a gene that controls the cell cycle can lead to uncontrolled cell 
growth, resulting in carcinogenesis, a process which ultimately gives rise to human cancer. Most 
of these mutations arise through error-prone mutagenic bypass of the lesions which is enabled by 
low fidelity translesion synthesis (TLS) DNA polymerases. 
         6-NC is metabolically activated by nitroreduction and a combination of ring oxidation and 
nitroreduction pathways. The nitroreduction pathway yields major DNA adducts at the C8 and N2 
positions of dG, N-(dG-8-yl)-6-AC and 5-(dG-N2-yl)-6-AC. The nitroreduction pathway also yield 
adduct at the C8 position of  dA, N-(dA-8-yl)-6-AC and a 2'-deoxyinosine (dI) adduct, N-(dI-8-
yl)-6-AC; which is believed to be a product of deamination of the adenine adduct N-(dA-8-yl)-6-
AC. The N-(dA-8-yl)-6-AC adduct is particularly interesting, a nucleotide excision repair assay 
demonstrated that it is repaired much more slowly than many other bulky DNA adducts, including 
other DNA adducts formed by 6-NC. Neither the total synthesis nor cellular replication properties 
of the N-(dA-8-yl)-6-AC or other adducts derived from 6-NC have ever been reported.   
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         Chapter 2 describes synthetic methods developed to access 6-NC modified nucleosides, 
phosphoramidites and oligodeoxynucleotides of the C8-dA adduct, N-(dA-8-yl)-6-AC employing 
an optimized Buchwald-Hartwig palladium catalyzed cross-coupling strategy, which provided a 
high yield of the protected N-(dA-8-yl)-6-AC adducted nucleoside. The protected N-(dA-8-yl)-6-
AC adduct was converted to the protected 3’-phosphoramidite monomer and site specifically 
incorporated into 12 and 15-mer oligodeoxynucleotides (ODNs) via automated solid-phase DNA 
synthesis. These oligodeoxynucleotides were purified by reverse phase HPLC followed by 
denaturing polyacrylamide gel electrophoresis and characterized by high resolution mass 
spectrometry.  
         Chapter 3 employs 2D NMR spectroscopy and DFT calculations to investigate the 
conformational preference of N-(dA-8-yl)-6-AC adducted nucleoside. We further investigated the 
helical structures of N-(dA-8-yl)-6-AC adduct in 12 and 15-mer oligodeoxynucleotide duplexes 
using circular dichroism (CD) spectroscopy. The stability of N-(dA-8-yl)-6AC adducted 
nucleoside was also investigated under biologically relevant conditions using UV/Vis 
spectroscopy and HPLC assays.  
         Chapter 4 describes investigation of the replication bypass efficiency of N-(dA-8-yl)-6-AC 
adduct in Escherichia coli and in human embryonic kidney (HEK293T) cells. The 15-mer 
containing N-(dA-8-yl)-6-AC modified oligodeoxynucleotide was used to construct single-
stranded shuttle vectors containing a single N-(dA-8-yl)-6-AC adduct site using recombinant DNA 
technology.  These recombinant vectors were replicated in Escherichia coli and HEK293T cells. 
The roles of several translesion synthesis (TLS) replication polymerases in adduct bypass was also  
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investigated via conducting replication experiments in isogenic cells where individual TLS DNA 
polymerases were depleted by the CRISPR/Cas9 genome editing method or siRNA knockdown 
approach.  
         Chapter 5 evaluates the mutagenicity and replication bypass efficiency of the ring opened 
formamidopyrimidine (Fapy.dG) adduct that is produced via oxidative stress in two interesting 
p53 mutation hotspot sequences that include codons 248 and 249. Fapy.dG modified 
oligodeoxynucleotides was used to construct single-stranded shuttle vectors containing a single 
adducted site and replicated in HEK293T cells.  
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Chapter 1 – Introduction 
1. 1 DNA Damaging Agents  
         DNA is the repository of all the genetic information in living cells. Thus, its structural 
integrity and stability are essential to life.1,2 However, DNA is not an inert entity, and therefore 
may become damaged by reactive chemical modalities that are generated in cells or that may enter 
cells from exogenous sources. Exposure to a variety of DNA damaging agents can lead to an 
estimated rate of up to 100,000 lesions per cell per day.2 This status quo requires a constant 
excision and replacement of damaged residues by DNA repair machinery in order to counteract 
potentially genotoxic and mutagenic outcomes. The reaction of genotoxic agents with DNA result 
in a plethora of lesions, commonly referred to as adducts. Endogenous agents include chemicals 
generated from normal cellular processes such as respiration and lipid peroxidation.3,4 These 
processes generate reactive oxygen species (ROS) that may damage DNA. Genomic DNA may 
also be assaulted by exogenous or environmental agents.5 The main perpetrators are ionizing 
radiation and genotoxic chemicals that may enter cells. Genotoxic chemicals are often 
metabolically activated in cells to form reactive metabolites that engage DNA in chemical 
reactions resulting in covalent linkages to specific sites of the four nucleotides (dNTPs) of DNA 
to generate DNA adducts or lesions.6–8  
 
Figure 1. Types of DNA damages from endogenous and exogenous agents 
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1. 2 Carcinogenicity of Nitroaromatic compounds 
         DNA damage by genotoxic chemicals can become important in the development of 
biologically relevant events and human cancers.7,9 Many nitroaromatic hydrocarbons (NO2-PAH) 
are known to induce tumors in experimental animals.7,10,11 Nitroaromatic compounds are 
environmental pollutants that are present in many mixtures such as cigarette smoke, coal fly ash, 
diesel exhaust and have also been detected in burnt grill food. Notably, drugs containing 
nitroaromatic motifs have also been marketed worldwide. Thus, human exposure to nitroaromatic 
compounds is inevitable.12  
 
Figure 2. Examples of nitroaromatic compounds 
 
In the postindustrial era, food appears to be the most significant source of NO2-PAH exposure. In 
addition, simultaneous exposure to PAH and nitrogen oxide gas appears to lead to endogenous 
formation of NO2-PAH.8,12  
         In cells, most nitroaromatic compounds are metabolically activated to reactive modalities via 
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compounds. Notably, significant difference in the enzymes responsible for nitroreduction and 
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oxidation has been observed in different organisms. In humans, xanthine oxidase and microsomal 
NADPH-cytochrome c have been identified as the enzymes responsible for nitroreduction, while 
the cytochrome P450 family of enzymes is predominantly responsible for the oxidative 
metabolism of these compounds.9,12,13  
1. 3 6-Nitrochrysene  
        6-Nitrochrysene (6-NC) belongs to the family of NO2-PAH above. 6-NC is a potent mutagen 
in bacteria. It is an exceptionally potent carcinogen in newborn mice, and it induces mammary 
carcinoma in rats. The genotoxicity of 6-NC is derived from its ability to chemically react with 2’-
deoxyguanosine (dG) and 2’-deoxyadenosine (dA) in DNA to generate DNA-carcinogen adducts 
(Scheme 1).13–15  
 
Scheme 1. Metabolic activation of 6-nitrochrysene via nitroreduction and ring oxidation 
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         Several in vivo studies in mice and rats have demonstrated that 6-NC can be activated by two 
major pathways. These include a nitroreduction and a nitroreduction-ring oxidation tethered 
pathway (Scheme 1).13 The nitroreduction pathways involves a simple nitroreduction of 6-NC to 
form the corresponding N-hydroxy-6-aminochrysene (N-OH-6-AC). This N-OH-6-AC 
electrophilic species reacts with the nucleophilic C8-site of purines bases in dG and dA to generate 
DNA adducts, N-(dG-8-yl)-6-AC (1), and N-(dA-8-yl)-6-AC (3). Adduct 3 is believed to give rise 
to the corresponding 2'-deoxyinosine adduct N-(dI-8-yl)-6-AC (3’), but whether the process of 
deamination is enzymatic or non-enzymatic has never been established. N-OH-6-AC electrophilic 
species also reacts at the N2 site of dG to form 5-(dG-N2-yl)-6-AC (2). Additional adducts are 
formed by a combination of ring oxidation and nitroreduction (Scheme 1).13,14,16  
 
Scheme 2. Generation of nitrenium ion as ultimate carcinogen 
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        As with many nitroaromatic compounds, metabolic activation via nitroreduction of                        
6-nitrochrysene to its N-hydroxy-6-aminochrysene, N-OH-6-AC (Scheme 1) is a proximate 
carcinogen which can react with nucleobases in cellular DNA to induce DNA adducts. However, 
it is believed that the N-hydroxy-6-aminochrysene species is further activated by O-esterification 
or N,O-diesterification enabled by cellular enzymes such as the acetyl- and sulfotransferases 
(Scheme 2). The sulfonylhydroxyamines (Scheme 2) spontaneously undergo heterolytic N-O 
fission to form highly reactive nitrenium ions, which is the ultimate carcinogen species that react 
with DNA molecules to form the corresponding DNA adducts.17,18 
 
         Intramammary administration of 6-NC metabolites resulted in the formation of mammary 
tumors at the site of injection (Table 1). The carcinogenic potency of 6-NC and its nitroreduction 
and ring-oxidation metabolites toward the mammary gland of rats was ranked in the following 
order: 6-NC > 1,2-DHD-6-NC > 6-AC > 6-NCDE > 1,2-DHD-6-AC (Figure 3). Taken together, 
these results suggest that metabolites derived from both ring-oxidation and nitroreduction 
contribute to the overall carcinogenicity of 6-NC in the rat mammary gland. 7,10 
 
Figure 3. Carcinogenicity scale of 6-nitrochrysene (6-NC) and reactive metabolites.  
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Compounds Tumor Incidence (%) 
1. 6-NC 95.8 
      2.   1,2-DHD-6-NC 37.5 
3. 6-Ac 48 
4. 6-NCDE 16 
5. 1,2-DHD-6AC 28 
6. Control DMSO 0 
Table 1. Mammary tumor induction by 6-NC and reactive metabolites.10 
 
         6-Nitrochrysene is noticeably less abundant than other NO2-PAHs in the environment. 
However, it is the most potent NO2-PAH compound ever tested in the newborn mouse assay.10      
6-NC is much more active than chrysene, and any of the other mononitro-chrysene isomers and 
benzo[a]pyrene (B[a]P). It has been shown that 6-NC is a powerful mammary carcinogen in rats. 
In this study it was more potent than the extensively investigated ultimate carcinogen, the bay 
region diol epoxide of B[a]P. 6-NC is not only carcinogenic in mammary gland, it is tumorigenic 
in the colon of rats, and the lung and skin of mice.7,9,13 It is known that 6-NC can become 
metabolically activated in human liver and lung to form genotoxic metabolites.7,15  
         DNA lesions derived from 6-NC can play important roles in the development of human 
cancer if they are not repaired via cellular repair pathways such as nucleotide excision repair prior 
to DNA replication. These lesions can induce mutations in crucial sequences of cancer genes. 
Mutations in an oncogene, a tumor-suppressor gene such as p53, or a gene that controls the cell 
cycle can lead to uncontrolled cell growth, resulting in tumorigenesis.19,20 A large fraction of 
mutations in most human cancers involves mutations in the G:C base pairs of critical genes like 
p53 and a relatively smaller fraction of mutations occurs at the A:T base pairs.20–22 Indeed, 
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carcinogen-induced mutational signatures also predominantly involve G:C base pairs.23 Even so, 
mutations at A:T base pairs occur.  An example of a nitroaromatic compound derived mutations 
at the A:T base pair include aristolochic acid (AA), which forms N6-dA adducts. Mutational 
spectra of AA is dominated by A:T→T:A transversions in the p53 gene in urothelial tumors.22,24       
         Recently, an in vitro repair study by El-Bayoumy and coworkers showed that the efficiency 
of nucleotide excision repair (NER) of the C8-dA adduct, N-(dA-8-yl)-6-AC (3) is ~8 times lower 
than that of the C8-dG adduct, N-(dG-8-yl)-6-AC (1).  In fact, N-(dA-8-yl)-6-AC was estimated to 
be more resistant to NER than all other adducts formed by 6-NC and benzo[a]pyrene diol 
epoxide.14   
1. 4 DNA Repair Pathways and Genoprotective Networks  
1. 4. 1 Overview  
 
         DNA damages challenge the integrity of the genome and can stall replication and 
transcription machinery thereby inducing mutations and the onset of diseases. However, the 
process of evolution has equipped cells with the tools to identify and rectify DNA damages prior 
to DNA replication. In most cases, assaults on DNA are identified and cells elicit complex repair 
mechanisms that rectify damages. This mechanism is known as DNA damage response (DDR) 
and involves a series of coordinating enzymes, which removes DNA damages and reassemble 
DNA fragments.1 Thus, deleterious and mutagenic consequences of DNA damages are either 
minimized or completely eliminated. DNA damage signaling and cellular checkpoints coordinate 
DNA repair with cell-cycle transitions and can effectively halt the growth of a cell with damaged 
DNA until its DNA is repaired. The types of DNA lesion that results from a DNA damaging event 
controls the repair pathway elicited by cell’s repair machinery. DNA damages that results in 
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nucleobase alterations are usually removed by error-free pathways such as base excision repair 
(BER) and nucleotide excision repair (NER).3,4 
 1. 4. 2 Biological Consequences of DNA Damage  
 
         Despite cell’s robust and precise ability to identify and repair damaged DNA, some damages 
to DNA may escape cell’s repair machinery, particularly when the damages are induced at high 
frequency. Replication of damaged DNA that eludes cellular defense mechanisms poses a 
challenge to DNA replication.1,2 First, replication of unrepaired lesions cause mutations, which 
can result in genetic diseases. Second, DNA adducts can block replicative DNA polymerases, 
which are cellular workhorses responsible for copying DNA with high fidelity during replication. 
High fidelity replicative polymerases can fit only one templating nucleotide in their active site.25,26 
This favors accurate Watson-Crick-Franklin base pairing with incoming nucleotide of the newly 
made complementary strand of DNA. RNA and DNA polymerases blockages at replication forks 
can cause genome instability by chromosomal aberrations and can lead directly or indirectly to 
DNA strand breaks, which tend to be lethal in most cells.26,27  
          The detrimental biological consequences that DNA damage can present cells with is evident 
by the large commitment of genome protection expended by cell’s genoprotective networks 
including electrophile scavengers, recombination complexes that permit DNA lesion tolerance, 
specialized polymerases that enable lesion bypass and a large arsenal of DNA repair proteins.3 The 
inability of this protective network to effectively protect the genome can result in the onset of 
diseases.  
1. 4. 3 Base Excision Repair (BER) 
         In human cells, base modifications that’s are caused by endogenous agents such as reactive 
oxygen species (ROS) are generally removed by the base excision repair pathway.1–3 BER is 
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initiated by DNA glycosylases that hydrolytically cleave the base–deoxyribose glycosyl bond of a 
damaged nucleotide residue. This results in formation of an abasic site. The coordinated activities 
of AP endonuclease (APE1) and polymerase β then insert the correct base and the nicks are sealed 
by XRCC1-ligase 3 complex.28,29 The insertion of the appropriate base by polymerase β, can be 
accomplished in two different mechanisms, short-patch and/or long-patch repair. In short-patch 
repair DNA pol β performs a one nucleotide gap filling reaction and removes the AP site via lyase 
activity.29  
1. 4. 4 Nucleotide Excision Repair (NER)  
        The nucleotide excision repair pathway is mainly involved in the direct repair of bulky DNA 
lesions such as those induced by nitroaromatic chemical carcinogens, UV radiation and DNA 
damaging drugs. These distorting lesions thermodynamically destabilize DNA double helix and 
the enzymes involve in global NER utilize these perturbations to recognize and repair these lesions 
(Figure 4).30  
         As depicted in Figure 4, distorting lesions are directly recognized by the enzyme XPC-
RAD23B, which binds the nondamaged strand opposite the lesion. TFIIH interacts with XPC- 
RAD23B through protein-protein interaction and effectively forces the DNA helix wide open with 
its XPB subunit allowing XPD to slowly moves along DNA until its stalls at the damage site.  This 
stalling of XPD at the lesion allows for the formation of the pre-incision complex by recruitment 
of other enzymes such as XPA, RPA, and XPG which cooperatively makes an incision 5’ to the 
lesion. DNA repair synthesis is then initiated by Pol δ and Pol κ or Pol ε and associated factors, 
followed by 3’ incision by XPG. The newly synthesized strand is stitched to the undamaged strand 
by DNA ligase which seals the nick and completes the process.30,31  
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Figure 4. Mechanism of nucleotide excision repair in eukaryotes. Adapted from reference 28 
with permission from Cold Spring Harbor Laboratory Press.  
1. 5 Translesion Synthesis (TLS)  
         In order to evade the lethal consequences of excessive DNA damage, cells have developed a 
specialized mechanism known as translesion DNA synthesis (TLS), a pathway that is able to 
tolerate DNA damages in the genome by briefly replacing high fidelity replicative DNA 
polymerases with TLS polymerases.27,32 These specialized enzymes can bypass DNA lesions by 
inserting the correct or incorrect base opposites the lesion site.27,32,33 However, TLS polymerases 
are low fidelity enzymes which makes TLS an inherently error-prone process. Unlike replicative 
polymerases with tight binding sites, translesion polymerases have a solvent-exposed active site 
that is spacious enough to accommodate bulky DNA lesions, while enabling low fidelity and 
potential mutagenic replication.25  
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1. 5. 1 Translesion Synthesis in Mammalian Cells  
         When replicative polymerases such as eukaryotic Pol ε (Figure 5) stalls at the replication 
fork upon encountering a DNA lesion site, TLS polymerases are recruited to the site. TLS 
polymerases are recruited through protein-protein interactions with the replicative sliding 
processivity clamp (yellow).26,27  
 
Figure 5. Mechanism of Translesion DNA synthesis (TLS) in mammalian systems. Adapted from 
reference 24 with permission from Cold Spring Harbor Laboratory Press.26  
 
This is known as proliferating cell nuclear antigen (PCNA) in eukaryotes. In eukaryotic systems 
stalling of replicative polymerase causes the proliferating cell nuclear antigen (PCNA) to becomes 
ubiquitinated by the protein ubiquitin.26 This effectively signals the release of replicative 
polymerase from the sliding clamp of the replisome and recruit TLS polymerases to bind to the 
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replication fork.  These polymerases include Y family polymerases such as pol η, pol κ, pol ι, Rev1 
and the B family polymerase Pol ζ.26,27,33 TLS polymerases insert a correct or an incorrect base 
opposite the lesion. Translesion DNA synthesis is subsequently extended in the 5’ to 3’ direction 
past the lesion by the same TLS polymerase or a second TLS polymerase.26,33 After synthesizing 
a short sequence of DNA, all TLS polymerases are dissociated from the replication fork and 
replaced with high fidelity replicative polymerase to resume DNA synthesis.  
Polymerase η 
 
         Polymerase η (Pol η) is a Y-family polymerase and is the most extensively studied TLS 
polymerase. Pol η bypasses UV-induced thymine-thymine cyclobutane pyrimidine dimers (CPD) 
with high efficiency and high fidelity.34 In fact, Pol η is capable of bypassing these lesions with 
higher accuracy than even undamaged DNA. In humans, the presence of mutations in the POLH, 
gene responsible for the expression of Pol η, is known to result in the variant form of xeroderma 
pigmentosum (XP)33,35, a disease associated with an increased incidence of skin cancer.  Pol η has 
been labeled as CPD bypass polymerase due to its ability to bypass the CPD lesions with high 
fidelity. However, Pol η have been shown to play important roles in mutagenic and error free 
bypass many other lesions, such as to bypass 8-oxodG,36  O6-MedG,37  benzo[a]pyrene-N2-dG,37  
and DNA lesions derived from cisplatin.38 
Polymerase κ 
   
          Polymerase κ (Pol κ) is found in all domains of life and is the most highly represented and 
strongly conserved of all the TLS Y-family polymerases.26 Pol κ is considered to be the most 
accurate y-family polymerase on processing undamaged DNA.27,34 Notably, Pol κ has the unique 
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capability in accurately bypassing various dG lesions, including C8-guanyl,39 N2-furfuryl-dG40 
and 8-oxo- guanine.33 
Polymerase ζ  
         Unlike most mammalian TLS polymerases which are low fidelity Y-family polymerases, 
polymerase ζ (Pol ζ) belongs to B-family class of polymerases. Notably, other B-family 
polymerases includes high fidelity replicative polymerases such as Pol delta (δ), epsilon (ε) and 
alpha (α).26,33,34 However, unlike these replicative polymerases, Pol ζ is error-prone and lacks 3’-
5’ exonuclease activity which makes it categorically a TLS polymerase. Pol ζ is a herterodimer 
composed of the Rev3 catalytic subunit and the Rev7 accessory subunit.  Many researchers have 
shown that Pol ζ participates in a variety of error-free and error-prone bypass of many DNA 
lesions.41,42  
1. 5. 2 DNA Damage Response in Escherichia coli 
 
 SOS Response  
         In E. coli DNA repair is regulated by the expression of a network of genes which are referred 
to as the SOS response. Induction of the SOS response involves more than forty independent SOS 
genes, most of which are responsible for the expression of proteins responsible for protection, 
DNA repair and TLS lesion bypass.43,44 Under normal growth conditions the SOS genes are 
expressed at a basal level. These levels increase significantly when the SOS genes box is turned 
on in response to genome damage. Thus, in bacterial systems the expression of TLS polymerases 
is regulated by SOS response.45   
         The expression of genes in the SOS box is regulated by the LexA protein. Under normal 
cellular conditions, LexA dimer is bound to the promoter region of the SOS box thereby inhibiting 
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gene expression (Figure 6).45,39 Upon encountering a replication blockage at the replication fork 
during DNA replication the RecA protein is activated to become a coprotease by formation of a 
filament of RecA on single-stranded DNA (ssDNA). RecA is a protease and facilitates the self-
cleavage reaction of LexA. As LexA repressor levels decrease, the SOS genes are expressed and 
induces DNA repair mechanisms, tolerance of DNA damage, and induced delay of the cell 
cycle.44,45 
 
Figure 6. Induction of SOS response in E. coli. Adapted from reference 43.  
  Translesion Synthesis in Escherichia coli       
         In E. coli, TLS low fidelity polymerases are Pol II, Pol IV and Pol V. When replicative 
polymerase Pol III (Figure 7) stalls at the replication fork upon encountering a site of a DNA 
lesion, TLS polymerases are recruited to the site.26,32 TLS polymerases are recruited through 
interactions with the replicative sliding processivity clamp (yellow). This is known as β-Clamp in 
E. coli. This signals the release of replicative Pol III from the sliding clamp of the replisome and 
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recruit TLS polymerases to bind to the replication fork. These polymerases include low fidelity 
polymerases are Pol II, Pol IV and Pol V. TLS polymerases insert a correct or an incorrect base 
opposite the lesion. Translesion DNA synthesis is subsequently extended past the lesion by the 
same TLS polymerase or a second TLS polymerase. After synthesizing a short sequence of DNA, 
all TLS polymerases are dissociated from the replication fork and replaced with high fidelity 
replicative polymerase to resume DNA synthesis.26  
 
Figure 7. Mechanism of Translesion DNA synthesis (TLS) in E. coli. Adapted from reference 30 
with permission from Cold Spring Harbor Laboratory Press. 
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1. 6 Scope of Dissertation  
         It is now clear that carcinogen-DNA adducts can interfere with DNA structure and affect the 
accuracy of DNA replication leading to heritable genetic changes and cancer. The overarching 
goal of my thesis research is to investigate the mechanisms of mutagenesis and DNA repair 
induced by DNA lesions in cells.  The multi-faceted nature of this goal requires tools in organic 
synthesis, analytical chemistry and molecular and cell Biology.  
         Chapter 2 of this thesis focus on the synthesis of site-specifically modified 
oligodeoxynucleotides containing C8-deoxyadenosine DNA adduct derived from 6-nitrochrysene 
(6-NC) modification. This lesion derives from the nitroreduction 6-NC to its reactive metabolite 
which subsequently reacts at the C8 site of 2’deoxyadenosine in DNA to generate N-(dA-8-yl)-6-
AC DNA adduct. This adduct is referred to as N-(dA-8-yl)-6-AC throughout this thesis. 6-NC is 
the most potent carcinogen ever tested in newborn mouse assay and is a potent mutagen in 
bacteria. DNA lesions resulting from 6-NC modifications can inhibit DNA replication and are 
likely to induce mutations if they are not removed by cellular defense pathways prior to DNA 
replication. The N-(dA-8-yl)-6-AC DNA adduct is particularly interesting; it has been showed to 
be poorly repaired in nucleotide excision repair assay in HeLa cells extract. Using phosphoramidite 
chemistry and solid phase DNA synthesis, I have successfully synthesized this N-(dA-8-yl)-6-AC 
adduct.  The key step in the synthesis of N-(dA-8-yl)-6-AC DNA adduct is a palladium-catalyzed 
Buchwald-Hartwig cross coupling reaction wherein carcinogenic 6-aminochrysene is coupled at 
the C8 site of protected bromo-dA. The 6-NC modified adduct, N-(dA-8-yl)-6-AC was converted 
to its corresponding 3’-phosphoramidite precursor and used to synthesize 12-mer and 15-mer 
oligodeoxynucleotides. These oligodeoxynucleotides were designed to mimic parts of the p53 
tumor suppressor gene with biologically relevant mutation hotspots. N-(dA-8-yl)-6-AC adduct 
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containing oligodeoxynucleotides were purified by reversed phase HPLC and denaturing 
polyacrylamide gel electrophoresis and characterized by high resolution mass spectrometry.  
         Chapter 3 address the biophysical characterization of the 2’-deoxyadenosine DNA adduct, 
N-(dA-8-yl)-6-AC.  In this section, 2D NMR spectroscopy and DFT calculations were used to 
investigate the conformational preference of N-(dA-8-yl)-6-AC adducted nucleoside. We further 
investigated the helical structure of N-(dA-8-yl)-6-AC adduct in the 12 and 15-mer 
oligodeoxynucleotide duplexes using circular dichroism (CD) spectroscopy. The stability of           
N-(dA-8-yl)-6AC adducted nucleoside was also investigated under biologically relevant 
conditions using UV/Vis spectroscopy and HPLC.  
         The focus of chapter 4 is to investigate the replicative bypass of N-(dA-8-yl)-6-AC adduct 
in E. coli and human embryonic kidney cells, HEK293T cells. The 15-mer oligodeoxynucleotide                 
(5’-GCCCTCAA*CAAGATG-3’) where A* = N-(dA-8-yl)-6-AC  adduct was used to construct a 
single-stranded shuttle vector containing a single adducted site using recombinant DNA 
technology and replicated in cells. The DNA sequence of the 15-mer was chosen from TP53 gene 
codon 129-133, because crops contaminated with another nitroaromatic carcinogen aristolochic 
acid (AA) causes A→T mutation in codon 131 in patients with urothelial tumors. In Escherichia 
coli, viability of N-(dA-8-yl)-6-AC modified vector was ~60% of the control, indicating slower 
translesion synthesis of the adduct, which increased to nearly 90% upon induction of the SOS 
functions. N-(dA-8-yl)-6-AC DNA adduct is mutagenic in E. coli. The major type of targeted 
mutation is A*→G in both uninduced and SOS-induced cells.  
          The roles of translesion synthesis DNA polymerases in bypassing the 6NC modified C8-2'-
deoxyadenosine adduct, N-(dA-8-yl)-6-AC in HEK293T were also investigated in chapter 4. 
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Replication of plasmid containing a single site-specific N-(dA-8-yl)-6-AC adduct in HEK293T 
provided ~12 % progeny plasmid with mutations largely A*→T transversions. A 4-fold decrease 
in mutation frequency was observed when the plasmid is replicated in polymerases κ or ζ deficient 
cells. Similar experiments in polymerase η KO cells showed a 1.5-fold increase in mutation 
frequency. We also noted that plasmid replication in polymerases ζ KO and κ siRNA KD cells 
resulted in a 10-fold decrease in mutation frequency. Taken together, these results suggest that 
polymerases κ and ζ are cooperatively involved in the error-prone TLS of N-(dA-8-yl)-6-AC, while 
pol η is performs error-free bypass. 
         Chapter 5 evaluates the mutagenicity and replication bypass efficiency of the ring opened 
formamidopyrimidine (Fapy.dG) adduct that is produced via oxidative stress. DNA sequences:    
5’-AAC CG*G AGG CCC-3 and 5’-AAC CGG AG*G CCC-3 with codon 248 and 249 
(underlined) respectively of the tumor suppressor gene p53  was incorporated into a plasmid and 
replicated in human embryonic kidney 293T cells, which showed that Fapy.dG DNA adduct is 
mutagenic inducing largely G*→T transversions. Furthermore Fapy.dG adduct in CG*G sequence 
context (codon 248) induce mutations at ~50% greater frequency than AG*G in codon 249.  
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Chapter 2  
 Total Synthesis of Site-Specific Oligodeoxynucleotides Containing C8-2'-Deoxyadenosine 
Adduct Formed by 6-Nitrochrysene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Powell, B.V.; Basu, A.K. “6-Nitrochrysene-Derived C8-2’-Deoxyadenosine Adduct: Synthesis 
of Site-Specific Oligodeoxynucleotides and Mutagenicity in Escherichia coli. 2020 Chem Res 
Toxicol [In Press] 
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2.  Abstract  
 
         The environmental pollutant, 6-nitrochrysene (6-NC) is a potent mutagen in bacteria and it 
induces mammary carcinoma in rats. It is an exceptionally potent carcinogen in newborn mice.    
6-NC is metabolically activated by two pathways, which include only nitroreduction and both 
nitroreduction and ring oxidation. The nitroreduction pathway generates dG-C8, dG-N2, and the 
dA-C8 adduct, N-(dA-8-yl)-6-AC. Here, we report the synthesis of the phosphoramidite monomer 
of the C8-dA adduct of 6-NC from dA in 10 steps and its incorporation into oligodeoxynucleotides. 
The key step in the synthesis of oligodeoxynucleotides containing N-(dA-8-yl)-6-AC was 
palladium-catalyzed Buchwald-Hartwig cross coupling chemistry, which was optimized to 
achieved in 85% yield. The protected N-(dA-8-yl)-6-AC derivative was deprotected and then 
converted to appropriately protected phosphoramidite monomer for solid-phase DNA synthesis. 
The resulting phosphoramidite was used to synthesize a 12-mer and a 15-mer oligonucleotide. The 
adduct-containing oligodeoxynucleotides were purified by reversed phase HPLC followed by 
denaturing polyacrylamide gel electrophoresis and characterized by mass spectrometry.  
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2. 1 Introduction  
2. 1. 1 Buchwald-Hartwig Cross-Coupling Chemistry 
 
 
 
Scheme 3. Examples of arylamine C8-dA Buchwald-Hartwig cross coupling reactions          
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         The Buchwald-Hartwig palladium catalyzed C-N bond formation strategy has been 
successfully applied by many researchers to synthesize various DNA adducts (Scheme 3).46–50  
This strategy involves protection of the reactive functionalities on the nucleoside substrate and any 
necessary functionalization that facilitates smooth coupling. The Buchwald–Hartwig reaction is a 
cross-coupling reaction where C-N bond of an arylamines or heteroarylamines is formed by the 
reaction of an aryl halide or triflate with a primary or secondary amine in the presence of a 
palladium (0) catalyst and a base (Scheme 4).51–53  
 
Scheme 4. Buchwald-Hartwig cross coupling reaction overview 
 
         Typically for carcinogen-DNA coupling, C-N bond connecting the NO2-PAHs carcinogen 
and the nucleoside base is installed via a Buchwald-Hartwig coupling reaction. The point of 
adduction of the purine bases varies. Nitroaromatic carcinogens-DNA attachments can occur at 
the C8 and N2 site deoxyguanosine (dG) or at the C8 and N6 deoxyadenosine (dA) as shown in 
Figure 8.  
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Figure 8. Site of adduction of nitroaromatic carcinogens with purine bases. 
  
         The Buchwald-Hartwig cross coupling reaction begins with oxidative addition of the aryl 
halide or triflate species to the palladium which increases the oxidation state of Pd from 0 to +2.   
This is followed by coordination of the amine to the palladium. An attack of amine on the 
palladium (II) complex kicks out the halide as a leaving group and react with a strong base in 
solution. Reductive elimination then produces the final aryl amine product and regenerates the 
catalyst (Figure 9).52,53   
 
Figure 9. (A) Buchwald-Hartwig cross-coupling catalytic cycle. (B) Commonly used ligands. 
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The most common chelating ligand used in nitroaromatic carcinogen-nucleobase Buchwald-
Hartwig cross coupling reactions is 2,2’-bis(diphenylphosphino)-1,1’-binapthyl (BINAP).54 
However, other ligands have also been used successfully. Generally, these ligands are bulky 
electron-rich dialkylbiaryl phospines.55,56  
2. 1. 2 Synthesis of Carcinogen Modified Oligodeoxynucleotides  
 
Biomimetic Postoligomerization  
 
         To investigate mutation outcomes in cells carcinogen modified oligodeoxynucleotides are 
often synthesized via a biomimetic postoligomerization stategy or using phosphoramidite 
chemistry. In a postoligomerization approach an unmodified oligodeoxynucleotide is directly 
reacted with a carcinogen or its reactive metabolite. The resulting oligomer is then purified and 
characterized. The recovery of these reactions is inherently low yielding and only a single reactive 
base is accommodated in the starting unmodified oligodeoxynucleotide. Multiple reactive bases in 
the unmodified oligo substrate increases the number of possible products exponentially which 
makes purification difficult and further decreases the yields.13,14,50  
Phosphoramidite Chemistry Method 
 
         The synthesis of site-specifically carcinogen modified oligodeoxynucleotides utilizing 
phosphoramidite chemistry and solid phase DNA synthesis is currently the gold standard for 
synthesizing modified oligodeoxynucletides.57 Phosphoramidite chemistry, developed in the 
1980s and later enhanced with solid-phase supports and automation, is the method of choice for 
DNA oligonucleotide synthesis.58–60 Unlike biosynthesis, which proceeds in 5' → 3' direction, 
solid phase DNA synthesis proceeds in the 3' → 5' direction according to the steps outlined 
in Figure 10. The synthesis cycle begins with detritylation, the 5'-DMT protecting group is 
removed from the first, solid-support-linked nucleoside. In step 2, coupling, the free 5'-OH of the 
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first, solid-support-linked nucleoside attacks the phosphorus of the incoming second nucleoside, 
displacing its diisopropylamino group. This is the step in which modified phosphoramidites can 
be introduced. In step 3, oxidation, the resulting phosphite triester is unstable and is converted to 
a stable phosphate triester, this allows the next cycle to proceed to step 1. However, before moving 
to the next cycle, unreacted nucleosides with 5'-OH on the solid support are acetylated or capped, 
thereby preventing elongation of sequences with deletion mutations. 
 
Figure 10. Synthesis cycle for solid-phase oligonucleotides synthesis. 
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2. 2 Material and Methods 
         All reagents were purchased from commercial chemical suppliers and used without further 
purification unless otherwise noted. All reactions were performed in round bottomed flasks sealed 
with rubber septa, under an atmosphere of nitrogen, and stirred with a TeflonTM-coated magnetic 
stir bar unless otherwise noted. Temperatures above 23 °C were controlled by a temperature 
modulator. Pre-dried tetrahydrofuran (THF), benzene, toluene, acetonitrile (MeCN), methanol 
(MeOH), and triethylamine (Et3N), were degassed with argon for 60 min. Reactions were 
monitored by thin layer chromatography (TLC) using J.T Baker 2.5 x 7.5 cm silica gel flexible 
TLC sheets and visualized using UV (254 nm). Volatile solvents were removed using a rotary 
evaporator under reduced pressure. Silica gel chromatography was performed using Sorbent 
Technologies 60 A, 230 x 400 mesh silica gel (40-63 μm). 
        1H NMR and 13C NMR were obtained in CDCl3 and DMSO-d6 on 400 MHz spectrometers 
with 13C operating frequencies of 100 MHz and analyzed using MestReNova. Chemical shifts are 
reported in parts per million (δ) relative to residual chloroform (7.26 ppm for 1H and 77.16 ppm 
for 13C). Data for 1H NMR spectra are reported as follows: chemical shift (multiplicity, number of 
hydrogens and assignment). Multiplicity is designated as s (singlet), d (doublet), t (triplet), q 
(quartet), p (pentet), or m (multiplet). High-resolution mass spectral (HRMS) data was obtained 
using electrospray ionization (ESI) and the data was analyzed using MassLynx. 
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2. 2. 1 Experimental Methods 
 
8-Bromo-2'-deoxyadenosine (4)  
Bromine (9.6 ml, 194.72 mmol) was added to freshly prepared 1M acetate buffer, pH 5.4 (190 ml) 
and stirred for 24 hours until completely dissolved. The bromine solution was added drop-wised 
to a slurry of 2’-deoxyadenosine (10.0 g, 37.13 mmol) in acetate buffer (100 ml). The reaction was 
monitored by TLC and was completed after 90 min. Solid sodium bisulfite was added to destroy 
excess bromine, then the reaction mixture was neutralized with 2N NaOH. The reaction mixture 
was then allowed to cool at -20 °C for 30 minutes. After this time the reaction mixture was filtered 
and washed with cold water and dried to yield a beige powder 2 (8.5 g, 69 %). TLC 
(CH2Cl2/MeOH, 80:20): Rf 0.56. 
HRMS (ESI+) m/z calc. for C10H12BrN5O3 [M+H] +, 330.1380; found, 330.0188.  
1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H,), 7.50 (s, 2H), 6.30 (t, J = 8.0, 6.4 Hz, 1H), 5.34 
(d, J = 4.2 Hz, 1H), 5.28 (dd, J = 7.7, 4.4 Hz, 1H), 4.49 (dt, J = 6.6, 3.2 Hz, 1H), 3.89 (td, J = 4.7, 
2.5 Hz, 1H), 3.66 (dt, J = 11.8, 4.5 Hz, 1H), 3.49 (ddd, J = 12.2, 7.8, 4.9 Hz, 1H), 3.25 (ddd, J = 
13.6, 8.0, 6.0 Hz, 1H), 2.20 (ddd, J = 13.1, 6.5, 2.7 Hz, 1H).   
13C NMR (101 MHz, DMSO) δ 155.38, 152.63, 150.38, 127.21, 120.17, 88.80, 86.83, 71.62, 
62.58, 37.46. 
8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (5) 
8-bromo-2’-deoxyadenosine, 4 (5.8 g, 17.508 mmol) and imidazole (5.685 g, 83.5175 mmol) were 
suspended in 15 ml of dry DMF. The reaction mixture was allowed to stir for 10 minutes. After 
this time, tert-butyldimethylsilyl chloride (7.26 g, 48.15 mmol) was added to the stirring mixture 
at room temperature. The solution turned transparent within 10-15 minutes and was allowed to stir 
for an additional 12-16 hours at room temperature. The reaction was monitored by TLC (90/10 
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CH2Cl2/MeOH). The solvent was evaporated under pressure and purified on silica gel column 
chromatography with a step gradient of methanol (0-6%) in DCM as the mobile phase. The product 
was isolated as light yellow solid (8.9 g, 90%).  
HRMS (ESI+) m/z calc. for C22H40BrN5O3Si2 [M+H] +, 559.1833; found 560.0100 
1H NMR (400 MHz, Chloroform-d) δ 8.23 (s, 1H), 6.38 (s, 2H), 6.34 (t, 1H), 4.86 (dt, J = 6.1, 3.9 
Hz, 1H), 4.06 – 3.77 (m, 2H), 3.77 – 3.45 (m, 2H), 2.22 (ddd, J = 13.1, 7.0, 4.2 Hz, 1H), 0.93 (s, 
9H), 0.81 (s, 9H), 0.13 (s, 6H), -0.02 (s, 3H), -0.06 (s, 3H). 
8-Bromo-3', 5'-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2'-deoxyadenosine (6)  
8-Bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyadenosine 5 (9.8 g, 17.442 mmol) and 4-
dimethylaminopyrine (42.2 mg, 0.3488 mmol) was dissolved in 20 ml of anhydrous pyridine. 4, 
4'-dimethoxytrityl chloride (8.9 g, 26.24 mmol) was added to the solution at room temperature. 
The reaction mixture was then allowed to stir at room temperature for 18 hours. After this time, 
TLC analysis indicated complete consumption of 5. The reaction mixture was concentrated in 
vacuo and the crude reaction mixture was purified on Al2O3 column chromatography with a step 
gradient of (0-12%) ethyl acetate (EtOAc) in hexanes. The product was isolated as a foamy and 
white solid (13.83 g, 92%).  
HRMS (ESI+) m/z calc. for C43H58BrN5O5Si2 [M+H] +, 861.0423; found 862.3206 
1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.46 – 7.06 (m, 8H), 6.94 – 6.66 (m, 5H), 6.34 (t, J 
= 6.7 Hz, 1H), 4.98 – 4.76 (m, 1H), 4.05 – 3.84 (m, 2H), 3.80 (s, 7H), 3.77 – 3.52 (m, 2H), 2.22 
(ddd, J = 13.0, 7.0, 4.3 Hz, 1H), 0.95 (s, 9H), 0.83 (s, 9H), 0.15 (s, 6H), -0.00 (s, 3H), -0.06 (s, 
3H).13C NMR (101 MHz, CDCl3) δ 158.53, 158.41, 158.32, 152.99, 152.90, 152.56, 151.96, 
151.83, 149.83, 149.52, 145.32, 145.14, 144.90, 142.33, 138.29, 137.37, 136.37, 136.11, 130.26, 
130.15, 130.12, 128.83, 128.31, 128.23, 127.88, 127.76, 127.72, 126.82, 126.79, 120.05, 113.20, 
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113.16, 113.05, 110.22, 108.06, 87.70, 86.49, 86.24, 85.01, 72.18, 72.12, 70.66, 62.50, 59.01, 
55.21, 36.89, 25.98, 25.90, 25.78, 25.74, 18.36, 18.08, -4.63, -4.68, -5.39, -5.45. 
 
General procedure for Optimization of Buchwald-Hartwig cross coupling reaction.  
8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyadenosine 5 (0.098 g, 0.1745 mmol) or 8-
bromo-3',5'-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2'-deoxyadenosine 6 (0.150 g, 
0.1745 mmol ), 6-aminochrysene ( 0.064 mg, 0.263 mmol ), Pd (0) catalyst (4 mol %) and rac-
2,2’-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, ) ( 12.5 mg, 0.02 mmol) were suspended in 
5 ml of anhydrous solvent (see Table 1). The solution was degassed by purging with argon for 1h. 
The reaction flask was then heated under argon at 85 – 100 °C for 1h. After this time sodium tert-
butoxide, NaOtBu or cesium carbonate, Cs2CO3 (0.263 mmol) was added and the reaction stirred 
at 85 – 100°C for an additional 1-2 hours. After this time, the reaction was monitored via TLC for 
consumption of compound 5 or 6. The reaction was then cooled, diluted with CH2Cl2 and filtered 
through Celite ®. The filtrate was allowed to evaporate in vacuo. For substrate 5, the crude mixture 
was purified on silica gel column chromatography with a step gradient (0 – 5%) methanol in 
dichloromethane. For substrate 6, the crude mixture was purified on Al2O3 column 
chromatography with a step gradient of EtOAc (0-10%) in hexanes as the mobile phase.  
 
8N-(6-aminochrysene)-3',5'-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2'-
deoxyadenosine (7b) 
8-Bromo-3',5'-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2'-deoxyadenosine 6 (0.595 g, 
0.693 mmol ), 6-aminochrysene ( 0.250g, 1.04 mmol ), palladium(II) acetate Pd(OAc)2 (6 mg, 
0.0276 mmol) and rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (50 mg, 0.080 
mmol) were suspended in 10 ml anhydrous toluene. The solution was degassed by purging with 
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argon for 1 h. The reaction flask was then heated under argon at 90°C for 1 h. After this time 
cesium carbonate, Cs2CO3 (0.366 g, 1.04 mmol) was added and the reaction stirred at 100°C for 
an additional 1hour. The reaction was cooled, diluted with ether and filtered through Celite ®. 
The filtrate was allowed to evaporate under reduced pressure. The crude mixture was purified on 
aluminum oxide column chromatography with a step gradient of EtOAc (0-10%) in hexanes as 
the mobile phase. The product was isolated as a dark green solid (0.603g, 85%).  
HRMS (ESI+) m/z calc. C61H70N6O5Si2 [M+H] +, 1023.5025.; found, 1023.5056 
1H NMR (400 MHz, CDCl3) δ 9.60 (s, 1H), 8.88 (d, J = 8.2 Hz, 1H), 8.74 (d, J = 8.3 Hz, 1H), 
8.70 (d, J = 9.2 Hz, 1H), 8.61 (s, 1H), 8.16 (dd, J = 8.1, 1.5 Hz, 1H), 8.03 – 7.92 (m, 3H), 7.81 – 
7.54 (m, 4H), 7.42 – 7.35 (m, 2H), 7.33 – 7.29 (m, 2H), 7.28 – 7.17 (m, 5H), 6.85 – 6.70 (m, 4H), 
6.65 (s, 1H), 6.53 (t, J = 7.8, 5.4 Hz, 1H), 4.23 (q, J = 3.3 Hz, 1H), 3.99 (dd, J = 11.4, 3.6 Hz, 1H), 
3.91 – 3.80 (m, 1H), 3.77 (s, 6H), 3.21 (ddd, J = 13.4, 7.8, 5.9 Hz, 1H), 2.51 (ddd, J = 13.0, 5.5, 
2.9 Hz, 1H), 0.96 (s, 8H), 0.61 (s, 8H), 0.16 (d, J = 4.6 Hz, 6H), -0.18 (s, 3H), -0.30 (s, 3H).13C 
NMR (101 MHz, Chloroform-d) δ 158.07 , 151.59 , 149.54 , 149.20 , 145.89 , 138.18 , 133.40, 
132.49 , 131.49 , 130.09 , 128.87 , 128.83 , 128.43 , 127.73 , 126.82 , 126.70 , 126.54 , 126.51 , 
126.30 , 126.11 , 125.33 , 123.99 , 123.53 , 121.38 , 121.01 , 118.71 , 113.20 , 113.04 , 88.35 , 
85.60 , 72.43 , 70.31 , 63.02 , 55.16 , 39.79 , 25.84 , 25.65 , 18.24 , 18.07 , -4.51 , -4.72 , -5.71 , -
5.76 . 
8N-(6-aminochrysene)-3',5'-O -bis(tert-butyldimethylsilyl)-2'-deoxyadenosine (7a)  
Method 1 
Fully protected coupled substrate, 8N-(6-aminochrysene)-3',5'-O-bis(tert-butyldimethylsilyl)-N6-
dimethoxytrityl-2'-deoxyadenosine, 7b (2.0 g, 1.95 mmol) was dissolved in 5.0 mL 
dichloromethane and to this added 1M zinc bromide solution in methanol: dichloromethane (1:1) 
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(6 mL). The reaction was stirred for 0.5 h and was monitored for completion by TLC (90/10 
DCM/MeOH, v/v).  The reaction was quenched with aqueous sodium bicarbonate and extracted 
with dichloromethane. The organic layer was combined and dried with sodium sulfate. The solvent 
was evaporated under reduced pressure and crude product was purified by silica gel flash column 
chromatography with a step gradient of 0-10% methanol in dichloromethane to afford compound 
6 as a beige powder (1.05 g, 75%).  
Method 2 
8-Bromo-3', 5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyadenosine 5 (0.098 g, 0.1745 mmol), 6-
aminochrysene ( 0.064 mg, 0.263 mmol ), tris(dibenzyldeneacetone)dipalladium (Pd2(dba)3 (6.4 
mg, 0.007 mmol) and rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) ( 12.5 mg, 0.02 
mmol) were suspended in 8 ml diethoxy ethane (DME). The solution was degassed by purging 
with argon for 1 h. The reaction flask was then heated under argon at 85 °C for 1 h. After this time 
cesium carbonate, Cs2CO3 (86 mg, 0.263 mmol) was added and the reaction stirred at 85°C for an 
additional hour. The reaction was cooled, diluted with dichloromethane and filtered through 
Celite®. The filtrate was allowed to evaporate under reduced pressure. The crude mixture was 
purified on silica gel column chromatography with a step gradient (0 – 5%) methanol in 
dichloromethane. The product 7a was isolated as a beige powder (71 mg, 56%) 
HRMS (ESI+) m/z calc. C40H52N6O3Si2 [M+H] +, 721.37; found, 721.3729 
1H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.74 (dd, J = 23.0, 8.6 Hz, 
3H), 8.42 (s, 1H), 8.25 (d, J = 1.9 Hz, 1H), 8.16 (d, J = 7.9 Hz, 1H), 8.00 (t, J = 9.4 Hz, 3H), 7.81 
– 7.60 (m, 5H), 6.64 (dd, J = 8.4, 5.4 Hz, 1H), 5.30 (d, J = 15.9 Hz, 1H), 4.67 (dd, J = 5.9, 2.9 Hz, 
1H), 4.22 (d, J = 2.9 Hz, 1H), 4.05 (dd, J = 11.5, 3.0 Hz, 1H), 3.88 (dd, J = 11.5, 2.8 Hz, 1H), 3.12 
(dt, J = 14.0, 7.1 Hz, 1H), 2.54 – 2.40 (m, 1H), 0.98 (s, 9H), 0.56 (s, 9H), 0.17 (d, J = 8.7 Hz, 6H), 
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-0.24 (s, 3H), -0.33 (s, 3H).13C NMR (101 MHz, CDCl3) δ 158.53 , 158.32 , 152.99 , 151.96 , 
145.32 , 142.33 , 137.37, 136.11 , 130.15 , 130.12 , 128.83 , 128.23 , 127.88 , 127.76 , 126.82 , 
126.79 , 120.05 , 113.20 , 113.16 , 113.05 , 110.22 , 108.06 , 87.70 , 85.01 , 72.12 , 70.66 , 62.50 
, 59.01 , 55.21 , 36.89 , 25.90 , 25.78 , 25.74 , 18.36 , 18.08 , -4.63 , -4.68 , -5.39 , -5.45. 
8N-(aminochrysene)-2'-deoxyadenosine (3) 
8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-2'-deoxyadenosine 7a (200 mg, 
0.2772 mmol) was dissolved in 3 ml of anhydrous tetrahydrofuran. 0.416 ml of 1M 
tetrabutylammonium fluoride in tetrahydrofuran was added and the reaction was allowed to stir 
for 24 hours under N2. After this time, the solvent was evaporated under reduced pressure and the 
crude product was purified via silica gel column chromatography with methanol (0-5%) in 
dichloromethane. The product was isolated as a light brown solid (116 mg, 85%).  
MS (ESI+) m/z calc. C28H24N6O3 [M+H] +, 493.53; found, 493.53 
1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 9.01 (d, J = 8.4 Hz, 1H), 8.89 (d, J = 7.4 Hz, 2H), 
8.84 (d, J = 8.2 Hz, 3H), 8.19 (d, J = 8.2 Hz, 1H), 8.10 (t, J = 6.8 Hz, 2H), 8.02 (s, 1H), 7.84 – 
7.66 (m, 4H), 4.14 – 3.99 (m, 1H), 3.81 (d, J = 11.9 Hz, 1H), 3.10 (td, J = 15.5, 14.4, 8.3 Hz, 1H), 
2.30 (dt, J = 12.9, 6.9 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 153.75, 150.12, 150.02, 149.66, 
135.98, 132.38, 131.56, 130.00, 128.90, 128.53, 127.64, 127.43, 127.24, 127.12, 126.32, 124.26, 
124.18, 124.04, 121.74, 117.26, 116.87, 88.27, 84.32, 71.90, 62.20, 58.00, 55.38, 38.79.  
N6-Benzoyl-8N-(aminochrysene)-2'-deoxyadenosine (8) 
8N-(6-aminochrysene)-3',5'-O -bis(tert-butyldimethylsilyl)-2'-deoxyadenosine, 7a  
(445mg, 0.617 mmol) was dissolved in anhydrous pyridine (5 mL) under an atmosphere of 
nitrogen and benzoyl chloride (0.108 mL, 0.9255) was added dropwise. The reaction mixture was 
stirred for 4 h at room temperature. It was then diluted with dichloromethane (10 mL) and washed 
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with saturated sodium hydrogen carbonate solution, and the aqueous layer was extracted twice 
with dichloromethane. After removal of the dichloromethane under reduced pressure, morpholine 
(0.134 mL, 1.5425 mmol) was added and the resulting mixture was stirred at room temperature for 
2 h. After this time, the reaction mixture was diluted with dichloromethane (10mL) and then 
washed twice with 0.5M sodium dihydrogenphosphate solution. The aqueous layer was extracted 
three times with dichloromethane. After complete removal of the dichloromethane under reduced 
pressure, 100 mg, 0.1386 mmol of crude product was dissolved in 3 ml of anhydrous 
tetrahydrofuran. 0.416 ml of 1M tetrabutylammonium fluoride in tetrahydrofuran was added and 
the reaction was allowed to stir for 24 hours under N2. After this time, the solvent was evaporated 
under reduced pressure and the crude product was purified via silica gel column chromatography 
with methanol (0-10%) in dichloromethane. The product was isolated as a yellow solid (70 mg, 
85%).  
HRMS (ESI+) m/z calc. C35H28N6O4 [M+H] +, 597.2250; found, 597.2234 and [M+Na]+ 
1H NMR (300 MHz, DMSO-d6) δ 10.89 (s, 1H), 9.74 (s, 1H), 9.61 (s, 1H), 8.99 (d, J = 7.8 Hz, 
1H), 8.83 (d, J = 8.9 Hz, 2H), 8.58 (s, 1H), 8.29 (d, J = 7.6 Hz, 1H), 8.02 (t, J = 6.6 Hz, 5H), 7.79 
(s, 0H), 7.59 (dt, J = 14.5, 7.4 Hz, 1H), 7.43 (dt, J = 14.4, 7.6 Hz, 3H), 6.82 (t, J = 7.1 Hz, 1H), 
5.48 (d, J = 4.2 Hz, 2H), 4.57 (s, 1H), 4.12 (s, 1H), 3.91 – 3.59 (m, 3H), 3.27 – 2.97 (m, 1H), 2.42 
(dd, J = 12.9, 6.0 Hz, 1H).13C NMR (75 MHz, DMSO-d6) δ 151.51 , 148.95 , 145.54 , 134.07 , 
134.00, 132.54 , 132.42 , 131.26 , 130.18 , 128.84 , 128.75 , 128.36 , 127.60 , 127.35 , 127.20 , 
127.05 , 126.96 , 125.69 , 124.33 , 124.06 , 123.33 , 121.64 , 115.19 , 88.45 , 84.85 , 71.77 , 62.02 
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N6-Benzoyl-8N-(6-aminochrysene)-5'-O-dimethoxytrityl-2'-deoxyadenosine (9) 
The N6-benzoylated C8-arylamine-dA adduct 8 (0.295g, 0.494 mmol) was dissolved in anhydrous 
pyridine (6 mL) under a nitrogen atmosphere and 4,4’-dimethoxytrityl chloride (0.177g, 0.522 
mmol) and silver nitrate (0.089g, 0.522 mmol) were added. The mixture was stirred at room 
temperature until the reaction was complete (18 h). The reaction mixture then diluted with 
dichloromethane (10 mL) and washed with saturated sodium hydrogencarbonate solution and 
brine. The aqueous layer was extracted twice with dichloromethane. The organic layers were 
combined, dried over sodium sulfate, and filtered, and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography on silica gel eluting with 0-3% 
methanol in dichloromethane to afford the desired DMT protected 7 as a yellow foam, (328 mg, 
74%).  
HRMS (ESI+) m/z calc. C56H46N6O6 [M+H] +, 899.3552; found, 899.3532 
1H NMR (500 MHz, CDCl3) δ 9.31 (s, 1H), 8.76 (dd, J = 7.5, 1.3 Hz, 1H), 8.72 – 8.73 (m, 1H), 
8.44 (s, 1H), 8.23 (s, 1H), 8.16 (dd, J = 7.8, 1.3 Hz, 1H), 8.05 – 8.03 (m, 2H), 8.00 – 7.94 (m, 1H), 
7.89 (d, J = 9.2 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.66 – 7.62 (m, 2H), 7.54 – 7.42 (m, 3H), 7.42 – 
7.38 (m, 2H), 7.37 (d, J = 1.4 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.27 – 7.20 (m, 1H), 7.13 – 7.07 (m, 
4H), 6.87 – 6.81 (m, 4H), 6.60 (ddd, J = 4.0, 2.4, 0.9 Hz, 1H), 6.30 (s, 1H), 4.23 – 4.18 (m, 2H), 
3.82 (s, 6H), 3.68 (qd, J = 12.0, 3.1 Hz, 2H), 2.56 (dt, J = 12.5, 3.3 Hz, 1H), 2.31 (dt, J = 12.3, 5.1 
Hz, 1H), 1.91 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 165.57, 165.06, 158.21, 153.17, 152.09, 
151.83, 149.38, 144.96, 144.53, 143.84, 136.17, 135.10, 135.01, 134.11, 132.71, 132.45, 132.10, 
131.22, 130.09, 129.83, 129.77, 129.33, 128.49, 128.38, 128.24, 128.15, 127.68, 127.64, 127.01, 
126.80, 126.73, 126.41, 125.91, 125.50, 124.80, 123.68, 123.51, 123.13, 122.01, 121.90, 121.10, 
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120.62, 115.11, 112.85, 110.01, 86.81, 86.48, 85.69, 71.79, 67.62, 63.37, 63.30, 54.93, 53.49, 
53.07, 53.04, 53.02, 53.00, 52.93, 52.85, 52.83, 52.81, 52.79, 52.77, 40.96, 39.45, 0.01. 
N6-Benzoyl-8N-(6-aminochrysene)-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-
(cyanoethyl-N,N'-diisopropyl-phosphoramidite (10)  
This reaction was performed in a glove bag. N6-Benzoyl-8N-(6-aminochrysene)-5'-O-
dimethoxytrityl-2'-deoxyadenosine 9 (0.400 g, 0.444 mmol), N, N-diisopropylethylamine (0.155 
mL, 0.888 mmol) was dissolved in anhydrous dichloromethane (6 mL) under argon. 2-cyanoethyl-
N, N-diisopropylchlorophosphoramidite (0.105 mL, 0.444 mmol) was added and the reaction 
mixture stirred for 15 minutes. After this time, additional N, N-diisopropylethylamine (0.155 mL, 
0.888 mmol) was added to the solution and the reaction stirred for an additional 0.5 h.  After this 
time, the reaction mixture was diluted with dichloromethane (20 mL) and saturated sodium 
bicarbonate (25 mL). The organic layer was retained, and the aqueous layer was extracted twice 
with dichloromethane (2 x 15 mL). The organic layers were combined, washed with brine and 
dried over sodium sulfate. The solvent was concentrated under reduced pressure (2 mL).  The 
solution was added dropwise to a stirring solution of 220 mL hexanes. The resulting precipitate 
was collected and further purified on basified silica gel flash chromatography with a step gradient 
(0 -5%) methanol in dichloromethane containing 1% triethylamine. The product was isolated as a 
yellow solid (0.297 g, 61%) 
HRMS (ESI+) m/z calc. C65H63N8O7P [M+H] +, 1099.4636; found, 1099.4607 
31P NMR (162 MHz, CD2Cl2) δ 149.06, 149.01, 148.57, 148.51.  
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2. 2. 2 Synthesis of Site-Specifically Modified Oligodeoxynucleotides  
Phosphoramidite 10 was used to synthesize modified oligodeoxynucleotides as per manufacture’s 
instruction. However, the time of the coupling step was repeated extended to 15-min for the 
incorporation of modified phosphoramidite with total coupling efficiencies of > 95%. The 
unmodified and complementary oligodeoxynucleotide sequences were purchased from Integrated 
DNA Technologies, Inc in Coralville, Iowa, USA.  
2. 2. 3 Purification of Site-Specifically Modified Oligodeoxynucleotides  
The modified oligonucleotides were purified by reverse-phase HPLC and denaturing 
polyacrylamide gel electrophoresis (PAGE). The homogeneity of the purified modified and 
unmodified (control) oligodeoxynucleotides were confirmed via phosphorylation with T4 
polynucleotide kinase in the presence of [g32P] adenosine triphosphate and subsequent PAGE 
analysis. The modified oligodeoxynucleotides were further characterized by ESI mass 
spectrometry. HRMS data are given in Table 3. 
HPLC Purification  
 
The crude oligodeoxynucleotides were purified using reversed phase HPLC utilizing a C18 – semi 
prep column (Phenomenex Gemini –NX 5μ C18 (250 × 10 mm)) with an eluent of 0.1 M NH4OAc 
in ACN-H2O (solvent A) and 80% ACN-20% H2O (solvent B) with a linear gradient (0 to 50 min, 
2% to 30%) at a flow rate of 3.0 mL/ min monitored at both 254 nm and 340 nm. The purified 
oligomers were collected in several 1.5 mL microcentrifuge tubes and filtered through Amicon 
ultracel 3K filters. The filtrates were collected and dried in a SpeedVac. 
PAGE Purification  
After HPLC purification, the oligomers were purified by denaturing polyacrylamide gel 
electrophoresis. Modified and unmodified oligomers were loaded onto 20% PAGE (50 cm length) 
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containing 8M urea. The gel was run at 2250 V (45V/cm2) for 5~6 hours at room temperature until 
the leading dye bromophenol blue (which runs approximately with a 6mer) reached the bottom of 
the gel. The desired oligomer-containing band was visualized using a UV (254 nm) light and 
excised from the gel. The oligonucleotides were extracted from the excised gel by Spin-X (Costar 
Corning) columns and eluted with water, and subsequently desalted by passing through Sep-Pak 
C18 cartridges (Waters) with acetonitrile:water (60:40) . The elute from each sample was dried in 
a speed-vac and the concentration was determined by UV absorbance measurements.  The 
homogeneity of the purified modified and unmodified (control) oligodeoxynucleotides were 
confirmed via phosphorylation with T4 polynucleotide kinase in the presence of [g32P] adenosine 
triphosphate and subsequent PAGE analysis. 
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2. 3 Results and Discussion  
         In order to synthesize the C8-dA adduct of 6-NC in any desired DNA sequence, we employed 
a total synthesis approach. This approach involves the synthesis of the modified 3’phosphoramidite 
monomer which can be site-specifically incorporated in any desire oligodeoxynucleotide sequence 
via solid-phase DNA synthesis.  While many C8-dG adducts by different polycyclic aromatic 
amines and NO2-PAHs have been synthesized and incorporated in DNA by this method, 47,61–63 
there are only a few reports on the synthesis of dA adducts.  Notably, synthesis of several 
polycyclic aromatic hydrocarbons (PAH) derived DNA adducts at the 6 position of dA have been 
accomplished,62,64,65 but only Meier46 and Takamura17 have incorporated C8-arylamine-modified 
dA adducts in DNA by total synthesis.46  They used the Pd-catalyzed Buchwald-Hartwig C-N bond 
forming strategy to incorporate phenylamine derivatives and 4-aminobiphenyl at the C8 position 
of dA.  
 
Scheme 3.Preparation of Fully Protected Br-dA. 
         Selective bromination at C8 position of dA was achieved using Br2 in acetate buffer (pH 5.4.) 
Protection of the 3’, 5’ hydroxyls and exocyclic amine is necessary to avoid unwanted reaction in 
the Buchwald-Hartwig cross coupling reaction. Thus, silylation of 3’, 5’ hydroxyls moieties were 
achieved using tert-butyldimethylsilyl chloride. The N6-exocyclic amine was protected using 4,4′-
dimethoxytrityl chloride (DMTCl) in pyridine with catalytic amounts of 4-dimethylaminopyridine 
(DMAP), which provided fully protected dA substrate 6 for coupling.  
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2. 3. 1 Buchwald-Hartwig Cross-Coupling Reaction Optimization  
       We envisioned performing Buchwald-Hartwig cross-coupling reaction without protection of 
the N6 exocyclic amine as previously reported46,49. In order to increase the efficiency of the key 
palladium catalyzed Buchwald-Hartwig cross coupling reaction; a series of reaction conditions 
with respect to N6 protected or unprotected substrate, catalyst, base, solvent and temperature were 
screened to determine the optimal reaction conditions (Table 2). Previous work have demonstrated 
that Pd2(dba)3/NaOtBu were good catalyst/base combo; while combination of Pd(OAc)2/Cs2CO3 
work best together46,50. Thus, Buchwald-Hartwig optimization were done with this framework in 
mind. Initially N6 exocyclic free amine substrate, 5 reacted with 6-aminochrysene (6-AC) with 
combinations of Pd2(dba)3/NaOtBu in toluene as solvent at 100 ˚C. The desired product was 
isolated with 45% yield (Table 2, entry 1). Identical reaction conditions except with combination 
of Pd(OAc)2/Cs2CO3 furnished the desired product with increased yield of 56% (Table 1, entry 2). 
Each reaction shown here was carried out for 3-4 h.  Longer reaction times (up to 24 h) led to 
significant tailing on TLC for reactions carried out at 100 °C in toluene, which is usually indicative 
of degradation of the product. In 1,2-DME (performed at 85°C) this tailing was not observed, and 
the reactions were allowed to run overnight. However, longer reactions times did not result in 
improvement in reaction yields.  
         For the Pd-catalyzed coupling of protected dG with polyaromatic amines, Gillet and Schärer 
showed that N2-DMT-protected dG provides excellent yield of the adduct,47 which we have used 
successfully for the synthesis of dG-1-aminopyrene adduct.50 So, to improve the coupling 
efficiency, the N6 exocyclic amine was protected using 4,4′-dimethoxytrityl chloride (DMT-Cl) in 
pyridine with catalytic amounts of 4-dimethylaminopyridine (DMAP) and then the N6 DMT 
protected Br-dA nucleoside, 6 was subjected to the Pd-catalyzed coupling. Gratifyingly, N6 
exocyclic amine DMTr protected substrate, 6 coupled with 6-AC with combination of 
 40 
Pd(OAc)2/Cs2CO3 in toluene to furnish the desired product with 85% yield at 100 oC for 3 h (Table 
2).  For the DMT protected Br-dA nucleoside (6) also longer reaction time did not improve the 
yield. We believe that the improved yields with N6 DMT protected substrate in the Buchwald-
Hartwig cross coupling reactions can be attributed to the increased solubility of the substrate in 
toluene (and DME) facilitated by the non-polar DMT group.  
 
aAll reactions were carried out for 3-4 h. 
N
NN
N
HN
O
HN
O-TBDMS
TBDMSO
R
N
NN
N
HN
O
TBDMS-O
Br
O-TBDMS
5
R
R = H (7a)
R = DMTr (7b)
NH2
+ Pd (0), Base
Solvent, T (ºC)
Entry R 
 
Catalyst 
(4 mol %) 
Base 
(1.5 equiv) 
Ligand 
(12 mol%) 
Solvent Temp. 
(˚C) 
%Yield 
1 H Pd2(dba)3 NaOtBu BINAP Toluene 100 45 
2 H Pd(OAc)2 Cs2CO3 BINAP Toluene 100 56 
3 H Pd2(dba)3 NaOtBu BINAP DME 85 52 
4 H Pd(OAc)2 Cs2CO3 BINAP DME 85 42 
5 DMT Pd2(dba)3 NaOtBu BINAP Toluene 100 75 
6 DMT Pd(OAc)2 Cs2CO3 BINAP Toluene 100 85 
7 DMT Pd2(dba)3 NaOtBu BINAP DME 85 68 
8 DMT Pd(OAc)2 Cs2CO3 BINAP DME 85 61 
Table 2. Optimization of Buchwald-Hartwig cross coupling reaction. 
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Figure 11. Mechanism of Buchwald-Hartwig cross coupling reaction of protected 8-bromo-2’-
deoxyadenosine and 6-aminochrysene (6-AC) 
 
2. 3. 2 Synthesis of Modified Phosphoramidite Monomer  
       With the optimized conditions in hand and an efficient strategy to access coupled product 7b; 
N6-excocyclic amine was deprotected using a 1 M solution of ZnBr2 to furnish 7a. To enable solid 
phase DNA synthesis, N6 amine was then protected with base-labile benzoyl group using benzoyl 
chloride in pyridine followed by treatment with morpholine to afford N6-benzoylated product; 
desilylation of the 5’- and 3’-hydroxyl was achieved using tetrabutylammonium fluoride (TBAF) 
in THF to furnish 8. To initiate DNA synthesis the 5’postion was protected with acid-labile DMTr, 
9. The corresponding 3’-phosphoramidite was prepared using 2-Cyanoethyl-N,N-
diisopropylchlorophosphoramidite to give phosphoramidite monomer 10 (Scheme 6).  
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Scheme 4. Synthesis of Corresponding 3’-Phosphoramidite 10 a) 1M ZnBr2 in 1:1 solution. 
MeOH:CH2Cl2, 30 mins, 75%; b) 1M TBAF in THF, RT, 24h, 85%; c) Benzoyl chloride (BzCl), 
pyridine, RT followed by treatment with morpholine, 2h d) 1M TBAF in THF, RT, 24h, 85%; e) 
4,4-dimethoxytritylchloride (DMTCl), pyridine, AgNO3, RT 24h, 74% f) 2-Cyanoethyl-N,N-
diisopropylchlorophosphoramidite, DIEA, CH2Cl2, RT, 1h, 61%. 
2. 3. 3 Synthesis of Oligodeoxynucleotides Containing N-(dA-8-yl)-6-AC Adduct 
         Fully protected N-(dA-8-yl)-6-AC phosphoramidite (10) was incorporated in the 12 and 15-
mer oligodeoxynucleotides with total coupling efficiency of > 95%. Oligodeoxynucleotide 
deprotection was done at 55°C with ammonium hydroxide for 24h to furnished modified 
oligodeoxynucleotides containing N-(dA-8-yl)-6-AC adduct (Scheme 7). During deprotection, 
0.25M 2-mercaptoethanol was added to avoid oxidative degradation. These modified 
oligodeoxynucleotides were purified by reverse-phase HPLC and PAGE and characterized by high 
resolution electrospray ionization mass spectrometry in negative mode (Table 3). 
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                  Scheme 5. Modified oligodeoxynucleotides deprotection and purification 
 
 
 
          
         The 12-mer sequence was taken from part of p53 tumor suppressor gene, 5’-GTG CG*T 
GTT TGT-3’ where the underlined part is codon 273, which is frequently mutated in many 
different types of human cancers. We replaced G* with A* so that mutations from A* can be 
compared with the G adduct. The 15-mer sequence (Table 3), 5'-GCC CTC AA*C AAG ATG-3' 
was taken from another part of p53, which include codon 131 (underlined).  Codon 131 is one of 
the rare mutation hotspots in which an adenine is mutated. This was discovered from mutation 
spectrum by aristolochic acid, a naturally occurring nitroaromatic compound and a dietary 
contaminant.22,24,62 
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Purification
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Oligodeoxynucleotides Calculated (M-3H)3- Observed (M-3H) 3- 
5'-GTG CAT GTT TGT-3' 3679.622 3679.627 
5'-GTG CA*T GTT TGT-3' 3921.922 3921.7274  
5'-GCCCTCAACAAGATG-3' 4542.800 4542.8010  
5'-GCCCTCAA*CAAGATG-3' 4784.100 4784.9298  
Table 3. HRMS-ES mass for modified and unmodified (control) oligodeoxynucleotides 
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Figure 12. Structures of modified oligodeoxynucleotides.  
 
2. 4 Conclusion  
In summary, we have reported an efficient strategy for the synthesis of C8-6-nitrochrysene adduct 
of 2‘-deoxyadenosine. The 6-aminochrysene carcinogen was introduced at the C8 site of 2’-dA 
using Buchwald−Hartwig palladium catalyzed cross-coupling chemistry. This optimized strategy 
provides efficient and convenient access to N-(dA-8-yl)-6-AC adduct. The corresponding 
3’phosphoramidite adduct of N-(dA-8-yl)-6-AC were site-specifically incorporated into 
oligodeoxynucleotides via. solid-phase DNA synthesis. 
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Chapter 3  
Conformational Preference and Stability of 6-Nitrochrysene C8-2’Deoxyadeosine Adduct 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Powell, B.V.; Basu, A.K. “6-Nitrochrysene-Derived C8-2’-Deoxyadenosine Adduct: Synthesis 
of Site-Specific Oligodeoxynucleotides and Mutagenicity in Escherichia coli. 2020 Chem Res 
Toxicol [In Press] 
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3. 0 Abstract  
 
         Carcinogen-DNA adducts that derive from covalent modifications of DNA nucleobase 
by  nitro polycyclic aromatic compounds are known to form bulky DNA adducts.  These adducts 
can assume various conformations in DNA helix which can be responsible for inducing a variety 
of mutagenic outcomes. We investigated the conformational preference of the C8-
2’deoxyadenosine nucleoside that derives from 6-nitrochrysene modification, N-(dA-8-yl)-6-AC. 
The adducted nucleoside showed syn conformational preference by NMR spectroscopy and DFT 
calculations. We also investigated the stability of N-(dA-8-yl)-6-AC adducted nucleoside using 
UV/Vis spectroscopy and HPLC. We determined that N-(dA-8-yl)-6-AC adduct is stable under in 
vitro biologically relevant conditions. We further investigated the helical structure of N-(dA-8-yl)-
6-AC oligodeoxynucleotide containing duplexes using circular dichroism spectroscopy.   The CD 
curves of the N-(dA-8-yl)-6-AC containing 12 and 15mer duplexes showed only slight deviation 
from the B type DNA helical structure of the unmodified duplex.  
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3. 1 Introduction  
        Nitrogen-linked arylamine C8-dG lesions can adopt three distinct conformations (Figure 13) 
depending on the orientation about the glycosidic (sugar-base) bond and the location of the bulky 
aryl ring system within the duplex.66 These adducts are known to possess conformational 
heterogeneity. This refers to the ability of nucleotides to adopt more than one conformational 
posture about the glycosidic bond.67–69 The two orientation nucleotides can typically adopt are anti 
and syn of the nucleobase to the sugar.66 The ability of nucleotides to assume different 
conformations is believed to be an important factor in mutation outcomes. Carcinogen-DNA 
adduct possesses altered biophysical properties compared to the precursor nucleoside.70–72 It is 
believed that the correlation between aryl ring size, adduct planarity, and sequence context regulate 
distribution in conformational preference. Wetmore and coworkers purports that the distribution 
in conformational preference of adduct greatly impacts repair propensity and mutational 
outcomes.66  
 
Figure 13. Depictions of three major conformations induced in N linked C8-aryl-dG adducts  
        
        The nucleotide excision repair (NER) efficiency of N-(dA-8-yl)-6-AC adduct (Figure 14) (3) 
is eight times less that the N-(dG-8-yl)-6-AC (1) in identical sequence context.14 This suggests that 
N-(dA-8-yl)-6-AC adduct (3) is potentially more mutagenic than N-(dG-8-yl)-6-AC (1).  
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Figure 14. Major DNA adducts derived from 6-NC via nitroreduction pathway 
 
In human cells, bulky DNA lesions derived from nucleobase modifications are subjected to NER 
that attempt to restores the integrity of DNA prior to DNA replication through a ‘cut and patch’ 
mechanism.4,31 NER in humans involve recognition of helix distorting DNA damages that recruits 
NER enzymes.73,74 This process involves as many as 30 distinct proteins in a large complex known 
as nucleotide excision repairosome. It is believed that local thermodynamic destabilization plays 
an important role in determining lesion recognition and subsequent excision efficiency.30 
Therefore, non-distorting conformers of adducts may escape NER repair, while distorting 
conformers may be more efficiently repaired. Thus, the equilibrium between conformations might 
help determine their potential carcinogenicity.68 We hypothesized that N-(dA-8-yl)-6-AC (3) 
adduct is less distorting that N-(dG-8-yl)-6-AC (1) in an identical sequence context and therefore 
results in less destabilization and so is poorly recognized by NER enzymes.  
         To test this hypothesis, we studied the intrinsic conformation of the adducted free nucleoside 
to establish the preferred conformation of the adducted nucleoside. Interestingly, Sproviero et. al. 
demonstrated that bulky C8-arylamine-dG prefers syn conformation as adducted nucleosides but 
prefers anti conformation in duplex DNA. Furthermore, we studied the conformation of N-(dA-8-
yl)-6-AC (3) using circular dichroism spectroscopy and molecular dynamics. Furthermore it has 
been suggested that N-(dA-8-yl)-6-AC adduct (3) undergoes spontaneous deamination to produce 
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a deoxyinosine derivative N-(dI-8-yl)-6-AC.14 We were interested in understanding this facile 
deamination. To this end, we’ve studied the stability of N-(dA-8-yl)-6-AC under physiological 
temperature and pH.  
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3. 2 Materials and Methods 
3. 2. 1 Synthesis of N-(dA-8-yl)-6-AC nucleoside 
See 2.2.1 [ Synthesis of compound 3] 
3. 2. 2 Synthesis of site-specifically modified oligodeoxynucleotides  
See 2. 2. 4 
3. 2. 3 DFT Calculations  
 
 
Figure 15. Structures and chemical numbering of N-linked DNA adduct at the C8-site of 2′-
deoxyadenosine 
To analyze the intrinsic conformational preferences of the adducts, the potential energy surface 
was mapped as a function of the θ (∠(N9−C8−N10−C11)) and φ (∠(C8−N10−C11−C12)) dihedral 
angles using nucleobase models and as a function of χ (∠(O4′−C1′−N9−C4)) and θ using 
nucleoside N-(dA-8-yl)-6-AC adducts.75 Specifically, surfaces were generated using B3LYP/6-
31G(d) optimizations by altering and constraining each dihedral angle from 0° to 350° in 10° 
increments. B3LYP/6-31G(d) has been successfully used to study the conformational landscape 
of several DNA adducts.66,68 However, the extended π-system in the adducts investigated in the 
present work suggest that more accurate modeling of dispersion forces may be required.68 
Therefore, all minima identified from the scans were subsequently fully optimized with both 
B3LYP and B3LYP-D3(BJ) using the 6-31G(d) basis set for comparison. The similarities in the 
key structural parameters obtained with both functionals support our use of B3LYP for the 
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computationally intensive scans. Regardless, more accurate relative energies were obtained for the 
fully B3LYP-D3 optimized minima with B3LYP-D3(BJ)/6-311+ G(2df,p), which include scaled 
(0.9813) zero-point vibrational energy (ZPVE) corrections.76  
       The initial nucleobase models were built using GaussView 5.0 by appending the bulky groups 
to the template guanine. The nucleoside models were built from the lowest energy con- formation 
obtained for the nucleobase models by replacing H9 with 2′-deoxyribose in the B-DNA 
conformation obtained in a previous conformational analysis (i.e., C2′-endo pucker, β 
(∠(H−O5′−C5′−C4′)) dihedral angle fixed to 180° and the dihedral angle at the 3′ terminus 
(∠(H−O3′−C3′−H3′)) locked to 60°). All DFT calculations were performed using Gaussian 09 
(revision D.01).  
3. 2. 4 Circular Dichroism Studies 
         The concentration of oligodeoxynucleotides were determined using NanoDrop 2000 
spectrophotometer.  Equal amount of two complementary strands (5 nmol) were dissolved in 
buffer [1 mL, NaH2PO4 buffer (10mM), NaCl (140 mM), EDTA (1mM), pH 6.6] and heated to 
70°C and then slowly allowed to cool to room temperature to enable annealing of the two strands. 
CD measurements were carried out at 25 °C and samples were scanned from 400 to 200 nm at 0.5 
nm intervals averaged over 5 s on a ChirascanTM V100.  
3. 2. 5 UV/Vis Spectroscopy Stability Studies  
In 50 mm phosphate-buffered saline (PBS), pH 7.3 (containing DMSO, which was necessary to 
enhance the solubility). While incubating both compound 3 and 2’deoxyadenosine as control at 
concentrations of 6mM at 37 °C, aliquots were taken at various time points, diluted with water to 
a final concentration of 0.3 mM and analyzed by their UV/Vis absorption spectra.77  
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3. 3 Results and Discussion  
 
 
Figure 16. Proton NMR spectrum of N-(dA-8-yl)-6-AC adducted nucleoside (3) highlighting 
conformationally relevant peaks  
 
         NMR data on C8-arylamine-dA adducts showed that with a single phenyl ring, the preferred 
conformation of the N-glyosidic bond is anti, but addition of an N-acetyl group replacing the amino 
hydrogen rotates it to syn conformation.46  To determine syn or anti preference of N-(dA-8-yl)-6-
AC, its conformation was investigated using ROESY-NMR spectroscopy. Figure 16 shows 1H 
NMR spectrum with of N-(dA-8-yl)-6-AC adducted nucleoside with conformationally relevant 
peak assignment, while Figure 17 shows the ROESY NMR spectrum with a cross-peak between 
H1' proton of the sugar and 6-AC amine tethered to the C8 site of dA, indicating a preference for 
syn conformation. Furthermore, no cross-peaks were observed between the H2 proton on 
nucleobase and the H1' proton on the sugar, typically observed for anti-conformation. These results 
indicate a preference of N-(dA-8-yl)-6-AC to exist in the syn conformation of the N-glyosidic 
bond, which was also reported for other bulky C8-arylamine modified nucleosides.78,79  
chrysene-NH C2-Adenine-H Sugar-H1’
7
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Figure 17. ROESY NMR spectra of N-(dA-8-yl)-6-AC adduct (3) in DMSO-d6 at 300 K 
 
        To determine the conformational preference of the adducted nucleoside, we attached the 6-
aminochyrsene moiety to the template for adenosine in the Gaussian quantum chemistry software 
and scanned over the O4′−C1′−N9−C4 dihedral in 10° increments.69,80 Consistent with the ROESY 
NRM data, we found that the syn conformation is the lowest energy conformer, and that the lowest 
energy anti conformer is significantly higher in energy (Figure 18). Interestingly, both are 
stabilized by an intramolecular hydrogen bond. At still considerably higher energy, there is a mix 
of syn and anti-conformers. These results qualitatively confirms the assignment of the syn 
conformation preference from experiment, which is also in agreement with similar adducted 
nucleosides.46,81 
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Figure 18. Potential energy surface scan around the deoxyribose-nucleobase bond of N-(dA-8-yl)-
6-AC adduct (3) 
 
Circular Dichroism (CD) Studies  
 
         The 15mer (5’-GCCCTCAACAAGATG-3’) unmodified and N-(dA-8-yl)-6-AC modified 
oligodeoxynucleotides (5’-GCCCTCAA*CAAGATG-3’) were allowed to anneal to their 
complementary strand, and the resultant duplexes were evaluated on a circular dichroism 
spectrometer (ChirascanTM V100). As shown in Figure 19 (Panel A), the CD spectra confirm 
overall B type DNA conformation of the unmodified control duplex and the N-(dA-8-yl)-6-AC 
containing duplex. For control duplex a positive Cotton Effect was observed at 280 nm with 
Level of Theory:
B3LYP/6-31G(d)
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negative one at 245 nm typically found in B type DNA. However, CD curve of the N-(dA-8-yl)-
6-AC containing  
 
Figure 19. CD curves of unmodified (red solid line) and modified (black solid line) 15-mer (Panel 
A) and 12-mer (Panel B) oligonucleotides (sequence shown in Table 2) after annealing with their 
complementary strand. The CD spectra of the single-stranded oligonucleotides are shown in black 
dotted lines.  
 
         Similarly, the 12mer (5’-GTGCATGTTTGT-3’) unmodified and N-(dA-8-yl)-6-AC 
modified oligodeoxynucleotides (5’-GTGCA*TGTTTGT-3’) were allowed to anneal to their 
complementary strand, and the resultant duplexes were evaluated on a circular dichroism 
spectrometer. Likewise, the positive and negative Cotton Effect consistent with canonical B-type 
DNA helical structure were observed for 12mer control (unmodified) and N-(dA-8-yl)-6-AC 
modified duplex. However, both 12mer unmodified and modified duplexes showed less structured 
helices than that of the 15mer duplexes.   
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Study of the Stability of N-(dA-8-yl)-6-AC Adducted Nucleoside  
        N-(dA-8-yl)-6-AC DNA adduct is believed to give rise to the corresponding 2'-deoxyinosine 
adduct, but whether the process of deamination is enzymatic or non-enzymatic has never been 
established.14,13 We investigated the stability of N-(dA-8-yl)-6-AC adducted nucleoside under 
biologically relevant conditions;  in aqueous solution of PBS buffer at nearly neutral pH at 37 °C. 
N-(dA-8-yl)-6-AC adducted nucleoside was incubated  in 50 mm phosphate-buffered saline (PBS), 
pH 7.3 containing 30% v/v DMSO, which was necessary to enhance the solubility. As shown in 
Figure 20, N-(dA-8-yl)-6-AC adducted nucleoside had an absorption maximum at λ = 268 nm. 
During incubation aliquots were taken at various time points, diluted with water to a final 
concentration of 0.3 mM, and analyzed by their UV/Vis absorption spectra. The absorption 
maxima remained constant over 180 hours suggesting that N-(dA-8-yl)-6-AC adducted nucleoside 
is stable under the experimental conditions. Samples from the UV/Vis experiments were injected 
into the HPLC to determine the presence of new peaks. However, only a single peak corresponding 
to N-(dA-8-yl)-6-AC adducted nucleoside standard was observed.  Thus, our biochemical in vitro 
assay suggests that N-(dA-8-yl)-6-AC is stable in aqueous solution at a pH of 7.3, which is the pH 
detected inside the nucleus and cytoplasm of healthy cells.82 N-(dA-8-yl)-6-AC adducted 
nucleoside does not undergo spontaneous deamination to deoxyinosine derivative under the 
conditions described. However, further studies need to be performed in order to unequivocally 
confirm the stability of N-(dA-8-yl)-6-AC.  
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Figure 20.  A) Overlay of the absorption spectra of N-(dA-8-yl)-6-AC adducted nucleoside 
measured at the indicated time points; incubation of the compound (6 mM) in water at 37°C; for 
each measurement aliquots were taken and diluted with water to a final concentration of 0.3 mM 
B) Plotted data taken from the absorption measurement: intensity of absorption at λ = 268 nm 
against incubation time. 
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3. 4 Conclusion  
         Using ROESY NMR spectroscopy, we determined that the adducted purine prefers syn 
conformation of its glyosidic bond of N-(dA-8-yl)-6-AC in solution. The CD spectra of N-(dA-8-
yl)-6-AC 15-mer and 12-mer  containing duplexes were consistent with B-DNA, although N-(dA-
8-yl)-6-AC modified duplexes showed small deviations from the control duplexes, suggesting less 
structured helices for both 12 and 15-mer. In addition, we determined that N-(dA-8-yl)-6-AC 
nucleoside is stable under in vitro biologically relevant conditions.  
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Chapter 4  
Translesion Synthesis and DNA Repair of 6-Nitrochrysene-Derived C8-2′-Deoxyadenosine 
Adduct in E. coli and Human Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Powell, B.V.;Basu, A.K. “Translesion Synthesis and DNA Repair of 6-Nitrochrysene Derived C8-2’-
Deoxyadenosine Adduct in Human Cells.” [Manuscript in preparation] 
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4.  Abstract  
         DNA lesions resulting from 6-NC modifications can inhibit DNA replication and are likely 
to induce mutations if they are not removed by cellular defense pathways prior to DNA replication. 
A previous in vitro study in HeLa cell extracts have shown that the C8-2'-deoxyadenosine DNA 
adduct derived from 6‑nitrochrysene is more resistant to nucleotide excision repair (NER) than the 
corresponding C8-2'-deoxyguanosine DNA adduct. In this study, we investigated the replication 
bypass efficiencies and the roles of translesion synthesis (TLS) DNA polymerases in bypassing 
the 6NC modified C8-2'-deoxyadenosine adduct, N-(dA-8-yl)-6-AC in human embryonic kidney 
cells (HEK293T). We further investigated the mutagenicity and translesion synthesis (TLS) 
efficiency of N-(dA-8-yl)-6-AC in E. coli to compare mutation signature in E. coli with mutations 
induced in human cells. Replication of plasmid containing a single site-specific N-(dA-8-yl)-6-AC 
adduct in HEK293T provided ~12 % progeny plasmid with mutations largely A→T transversions. 
We observed 4-fold decrease in mutation frequency when the plasmid is replicated in polymerases 
κ or ζ HEK293T KO cells. Similar experiments in polymerase η KO cells showed a 1.5-fold 
increase in mutation frequency and a 38% decrease in TLS bypass efficiency. We also noted that 
plasmid replication in polymerases ζ KO and κ siRNA KD cells resulted in a 29% decrease in TLS 
bypass efficiencies and 10-fold decrease in mutation frequency. Taken together, these results 
suggest that polymerases κ and ζ are involved in the error-prone TLS of N-(dA-8-yl)-6-AC, while 
pol η is performs error-free bypass. In Escherichia coli, viability of the adducted construct was 
~60% of the control, indicating slower translesion synthesis of the adduct, which increased to 
nearly 90% upon induction of the SOS functions. Without SOS, the mutation frequency (MF) of 
the adduct was 5.2%. With SOS, the targeted MF increased 3-fold to 9.0%. The major type of 
targeted mutation was A*→G in both uninduced and SOS-induced cells.     
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Chapter 4 – Introduction 
4. 1 Introduction  
         Ubiquitous environmental contaminants such as nitropolycyclic aromatic hydrocarbons 
(NO2-PAH) are known to induce mammary cancer in rats and must therefore be regarded as 
potential human carcinogens.7,16,83 A representative example of NO2-PAH is 6-nitrochrysene (6-
NC).  It is now clear that 6-NC is activated in cells not only from simple nitroreduction but also 
from a combination of ring oxidation and nitroreduction.13,14  
 
                 Figure 21. Nucleotide excision repair of 6-NC DNA adducts in HeLa cell extracts.14  
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         El-Bayoumy and coworkers evaluated the nucleotides excision repair (NER) propensity of 
DNA adducts that is form from 6-NC in an in vitro study. They demonstrated that the N-(dG-8-
yl)-1,2-DHD-6-AC adduct is more resistant to NER than the N-(dG-8-yl)-6-AC adduct by a factor 
of∼2 and that the N-(dA-8-yl)-6-AC is much more resistant to repair since its NER efficiency is ∼8- fold lower than that of the N-(dG-8-yl)-6-AC adduct (Figure 20). Thus, the 6-NC-derived 
adenine adduct represents an example of the resistance of bulky DNA adducts to the human 
nucleotide excision repair system.14 This suggests that although N-(dA-8-yl)-6-AC adduct is 
formed in less abundance, it is more persistent in human cells.  As a result, it could be potentially 
more deleterious and mutagenic than the other more abundant DNA damages. DNA adducts that 
are resistant to NER are persistent in cells can stall replication machinery and might induce 
mutation at higher frequencies.  
         For over three decades it has been known that 6-NC is potent carcinogen in laboratory 
animals.13 However, little is known about the types and frequencies9,20 with which 6-NC induces 
mutations or the role of TLS enzymes in bypassing DNA lesions that derive from 6-NC in cells.   
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4. 2 Materials and Methods  
4. 2. 1 Materials  
Chemicals, enzymes, plasmid DNA and cells  
         All chemicals and reagents and enzymes were purchased from commercial suppliers and 
used without purification, unless stated otherwise. Chemicals for gel electrophoresis  such as 
agarose, Tris base, boric acid, Na2EDTA, urea, acrylamide, N,N’-methylene bisacrylamide, 
TEMED, APS), and preparation of biological media (e.g., agar, yeast extract, bactotryptone, 
sodium chloride) were purchased from Fisher Scientific (Agawam, MA). Phenol (UltrapureTM 
Buffer-Saturated Phenol) for phenol-chloroform extraction was obtained from Invitrogen. 
Hybridization buffer (PerfectHybTM Hybridization Buffer 1X) chloroform and isoamyl alcohol 
were purchased from Sigma-Aldrich (St. Louis, MO). [γ-32P] ATP for gel assays and 
hybridization were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA).  
         The media required for mammalian cell culture such as fetal bovine serum (FBS), Dulbecco’s 
modified Eagle’s medium (DMEM), non-essential amino acids (NEAA), penicillin/streptomycin 
(PS), Dulbecco’s phosphate buffer saline (D-PBS) solution, 0.25% trypsin-EDTA, Opti-MEM I 
Reduced Serum Medium and transfection reagent (LipofectamineTM 2000) were purchased from 
Invitrogen Corp. (Carlsbad, CA).  
         All enzymes needed for construct preparation and radiolabeling including EcoRV, EcoRI T4 
DNA ligase, T4 polynucleotide kinase (PNK), uracil DNA glycosylase (UDG), and exonuclease 
III (exo III) were obtained from New England Biolabs (Beverly, MA).  
         pMS2 plasmid was a gift from M. Moriya (SUNY, Stony Brook, NY).84  
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         Escherichia coli strain DH10B and DH12S were purchased from Invitrogen (Carlsbad, CA). 
HEK 293T cells were obtained from ATCC (Manassas, VA).  
         The E. coli strains used were AB1157 [F- thr-1 araC14 leuB6(Am) ∆(gpt-proA)62lacY1 tsx-
33 supE44(AS) galK2(Oc) hisG4(Oc) rfbD1 mgl51 rpoS396(Am) rpsL31(Strr) kdgK51 xylA5 mtl-
1 argE3(Oc) thi-1] were provided by G. Walker (MIT, Cambridge, MA).  
        The unmodified oligodeoxynucleotides were purchased from Integrated DNA Technology 
(Coralville, IA) and Midland Certified Reagent Company (Midland, TX). The modified 
oligonucleotides were prepared as reported. Oligonucleotides were desalted using a Sep-Pak C18 
cartridge from Waters Corp. (Milford, MA).  
         Synthetic siRNA duplex against POLK (SI04930884), POLI (SI03033310) was purchased 
from Qiagen (Valencia, CA) 
4. 2. 2 Methods 
Agarose gel electrophoresis for single-stranded vector analysis  
        Agarose gel electrophoresis was performed to analyze purity of the plasmid preparations and 
to determine the construct concentration. The ss-pMS2 vector analysis was performed in 1.1% 
agarose gels. The agarose gel (1.1% w/v, 0.66 mg agarose in 60 mL of 1x TBE) was casted on a 
horizontal gel apparatus and gel was allowed to solidify for 30 min. The sample was prepared by 
mixing 0.2 μg (2 μL) of the plasmid DNA with 2 μL of 6x loading dye (10mM Tris-HCl (pH7.6), 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA) diluted to 10 
μL with water. ss-pMS2 analysis gel was run at 110 V for 3 hours at room temperature. Following 
electrophoresis, the gel was stained with ethidium bromide (25 μg/μL in 500 mL water) for five 
minutes, de-stained for 30 min in 1x TBE, and the DNA bands were visualized by UV-light.  
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Bacterial electro-competent cell preparation and SOS induction  
Four milliliters of overnight E. coli culture, prepared from a single colony, was transferred to 200 
mL of 1x LB media. E. coli cells were grown to 1 × 108 cells/mL (~ 2 h) and then harvested by 
centrifugation at 5000g for 15 min at 0 oC. This procedure was repeated twice except the cells 
were resuspended in 40 mL ice-cold deionized water. The bacterial pellet was resuspended in 1 
mL of glycerol/water (10% v/v) and kept on ice until further use. For SOS response, the following 
additional steps were introduced after the first centrifugation. The cells were resuspended in 50 
mL 10 mM MgSO4 and treated with 50 J/m2 or 20 J/m2 of UV light (254 nm) in 25 mL aliquots 
in 150 × 50 mm plastic petri dishes. The cultures were incubated in Luria broth at 37 oC for 40 
min in order to express SOS functions maximally. Following SOS induction, these cells were 
centrifuged, deionized, and resuspended in glycerol/water in a similar manner as described earlier 
except all manipulations were carried out in subdued light.  
Large scale preparation of single-stranded pMS2 (sspMS2) vector  
         Single-stranded phagemid pMS2 DNA was prepared from E. coli JM109 with the aid of the 
helper phage M13K07 (NEB, Beverly, MA) as reported by Moriya.84 The pMS2 vector contains 
origins of replication for f1, ColE1, and SV40, which can be used for single stranded replication 
in E. coli, double stranded replication in E. coli and mammalian cells. It also contains neomycin-
resistant (neo) and ampicillin-resistant (amp) genes, which can be used for the selection of the cells 
containing the vector in mammalian and bacterial cells, respectively. In addition, it has the SV40 
early promoter, SV40 small tumor (T) antigen splice sites, SV40 early polyadenylylation sites, and 
a multiple cloning site with a hairpin loop, that allow digestion of the single-stranded vector with 
EcoRV  
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         Electrocompetent E. coli DH12S (Invitrogen) cells were thawed on ice and 50 μL of cells 
were mixed with 50 ng of double stranded replicative form (RF) of pMS2. Then this mixture was 
transferred to a pre-chilled 1-mm gapped electroporation cuvette and the electroporation was 
carried out under following conditions: 1.8 kV, 25 μF and 200 Ω. Immediately after electroporation 
1 mL of pre-warmed (37 °C) SOC medium (Invitrogen) was added, transferred to 14 mL culture 
tube and was grown at 37 °C in an orbital shaker at 225-250 rpm for 1 hour. From the resulting 
culture, 5.0 μL aliquot was plated on lx YT + ampicillin (100μg/ml) and incubated overnight at 37 
°C. The following day, about 100 colonies were scraped from the 1x YT plate using a sterile loop, 
inoculated to 2 L of ampicillin containing 2xYT media along with 1 mL of M13K07 helper phage 
(Invitrogen) and incubated at 37 °C. After two hours of growth, 100μg/mL kanamycin was added 
and the culture was incubated overnight for another 16 hours.  
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Figure 22. Workflow for the large-scale preparation of ssPMS2 plasmid. 
          The phage-infected culture was transferred to 250 mL centrifuge bottles, spun down at 
10,000 rcf (20 min, 15°C), the resulting supernatant was transferred to another 250 mL centrifuge 
bottle and centrifuged at the same condition. Supernatant from the second spin was transferred 2L 
flask containing 4% (w/v) polyethylene glycol (PEG) and 3.5 M NaCl. The mixture was stirred in 
ice for at least one hour to precipitate the phage particles. The resulting cloudy solution was 
centrifuged at 10,000 rcf (20 min, 4 °C) and the pellet obtained was re- suspended in the minimum 
volume (6 mL) of 1x Tris-EDTA (pH 7.6) buffer. Then the phage particles were re-precipitated 
with ice-cold 4% (w/v) PEG and 4 M NaCl for an hour and centrifuged at 10,000 rcf (20 min, 
4°C). The pallet obtained was re-suspended in 2.4mL of freshly prepared 1x Tris-EDTA (pH 7.6) 
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buffer and centrifuged for 10 min at 4°C and 10000 rpm. The resulting supernatant containing the 
phage particles was incubated with 0.625 μg/mL proteinase K (Invitrogen) for 16 hours and single-
stranded pMS2 was purified from the digested phage solution by a series of phenol: chloroform 
extractions, followed by ethanol precipitation. Finally, sspMS2 was re-suspended in 200 μL sterile 
deionized water and quantified on the UV spectrometer. After purification, the purity of the ss-
pMS2 was determined by the absorbance ratio of 260 nm to 280 nm followed by analysis on 1.1 
% agarose gel.  
Single-Stranded pMS2 modified vector construction  
 
Figure 23. Workflow for construction of modified recombinant vector. 
         The construction of modified pMS2 vectors containing site-specifically incorporated adducts 
were performed following the method developed by Moriya. For construction of the pMS2 with 
modified or unmodified 12mer insert, l00 μg (58 pmols) of sspMS2 DNA was digested with 800 
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units of EcoRV at 37 °C for 3 h followed by room temperature overnight (16h). An aliquot of the 
reaction mixture was run on an l% agarose gel to confirm the complete linearization of the circular 
vector. An equimolar ratio of a 58-mer scaffold containing deoxyuridinies in place of 
deoxythymidines was annealed to linear ssDNA in 50 mM NaCl by heating at 90 °C for 5 min 
followed by slow cooling to 9 °C over 16 h. Annealing of the scaffold generated a gapped duplex 
that contained a 12mer-gap with complementary sequence of the lesion to be incorporated. An 
aliquot of the gapped duplex was run on 1% agarose gel with a known amount of control plasmid 
(ss-pMS2). The amount of the gapped duplex was determined by comparing the net-intensity of 
the gapped duplex band to the net-intensity of the known control plasmid using the KODAK 
Digital ScienceTM-1D program. After determining the gapped duplex concentration, a 20-fold 
molar excess of the modified or unmodified 5'-phosphorylated 12mer insert was added and ligated 
at 16°C overnight with 2800 units of T4 DNA ligase. Unligated oligonucleotides were removed 
by being passed through Centricon 100 apparatus. Any residual uncut-circular or religated DNA 
was removed by additional round of EcoRV digestion. The scaffold was removed by enzymatic 
digestion with uracil DNA glycosylase (UDG, 05 units/μl) and exonuclease-III (0.5 units/μL) at 
16°C overnight. The resulting constructs were extracted with phenol: chloroform and precipitated 
with ethanol. The final constructs were resuspended in deionized distilled-water and were run on 
1% agarose gel. The amount of construct was quantified in a manner similar to the way gapped 
duplex was quantified.  
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       Figure 24. Agarose gel analysis for recombinant DNA construction 
Replication of modified vector in HEK293T cells  
         The HEK293T wild type and specific polymerase knock out (KO) cells were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 4 mM L-glutamine, and adjusted to 
contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, and 10% fetal bovine serum in. When it was 
about ~80% confluent, cells were washed with PBS (Invitrogen), harvested with 6 mL of Accutase 
and was seeded in 24-well plate (approximately 1 x 105 cells). The cells were grown to ~80% 
confluency in the 24 well plate and transfected with 100 ng of each construct using Lipofectamine 
cationic lipid reagent (Invitrogen) according to manufacturer’s instruction. Subsequent to 
transfection with control or lesion containing pMS2, the cells were allowed to grow at 37oC, 5% 
CO2 for 24 hours and the plasmid DNA was harvested using Qiagen DNA extraction kit.  
TLS Assay in Human Cells 
         The lesion-containing or control pMS2 vector was mixed with a single-stranded pMS2 DNA 
vector (internal control); a 23-mer oligodeoxynucleotide sequence different from the N-(dA-8-yl)-
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6-A containing sequence (or control) DNA sequence. The molar ratio of internal control vector to 
control vector was 1:1, and those for the internal control vector to N-(dA-8-yl)-6-AC containing 
vector was 1:3. The a 23-mer oligodeoxynucleotide vector was used as an internal control and 
gave equal number of progeny as the control vector. TLS efficiency was determined as the 
percentages of the colonies originating from the N-(dA-8-yl)-6-A containing plasmid relative to 
the internal control.  
Mutant screening by oligonucleotide hybridization  
Dot- blot hybridization was performed to identify the possible mutations at the lesion- site or at 
nearby locations in the progeny. In brief, appropriate amounts of liquid culture were plated on lx 
YT + ampicillin (100μg/mL) plates and incubated at 37 °C overnight (16-18 h). The resulting 
individual colonies were picked using sterile toothpicks into single wells of a 96-well plate (Fisher 
Scientific) containing 200 μl lx YT + ampicillin (100 μg/mL). The inoculated 96- well plate was 
then incubated at 37°C for a minimum of 3 hrs before blotting colonies onto filter paper. Using a 
96-well replicator (Boekel Scientific, Feasterville, PA), cultures in the 96-well plate were blotted 
onto sterile labeled Whatmann chromatography papers placed on lx YT + ampicillin (100 μg/mL) 
plates, in triplicates. The plates were incubated at 37 °C for 16 h for colonies to be replication on 
the filter paper. After overnight incubation, following procedure was carried out to fix DNA onto 
the filter paper. The filters were carefully lifted from the plates and subsequently transferred to 
(colony side up) 0.5 N NaOH, denaturing solution, for 12 mins, and to 0.5 M Tris-HCl (pH 7.5), 
neutralizing solution for 7 mins. Then the filters were washed twice with lx SSC for 4 mins with 
slow agitation (50 rpm) and once with 100% ethanol for 30 seconds before they were baked for 2 
hours at 80 °C. In-between each washing steps, except for two SSC washes, filters were drained 
and damped dry on paper towels (colony side up). Thereafter, each filter was placed separately in 
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a heat sealable bag and sealed with 6 mL of PerfectHybeTM hybridization buffer (Sigma) 
containing corresponding left, right or wild-type 32P-radiolabeled probe (10 pmol of probe/filter). 
Liquid in the sealed bags were spread evenly to entirely cover the filters and were allowed to 
hybridize to corresponding probe at its optimum hybridization temperature for a minimum of 4 
hours in the hybridization oven (ProblotTM 12). Then the filters were carefully removed from the 
bags and gently agitated (60 rpm) twice with 2x SSC+0.1% SDS, preheated to the hybridization 
temperature (THyb), for 10 mins. Finally, the filters were removed from the SSC solution, dried 
and exposed to autoradiography. Two left and right probes were used to select phages containing 
the correct insert, and transformants that did not hybridize with both the left and right probes were 
omitted. Any transformants that hybridized with the left and right probes but failed to hybridize 
with the wild-type probes were subjected to DNA sequence analysis.  
Transformation of modified vector in E. coli and progeny analysis 
         Competent E. coli cells were prepared as described earlier. To induce SOS, the cells were re-
suspended in 10 mM MgSO4 solution and aliquots were treated with UV light (254 nm) (20 J/m2) 
in plastic Petri dishes. The combined aliquots were incubated in Luria broth at 37° C for 40 min 
for maximum SOS induction. Following SOS induction, these cells were processed in a similar 
manner, except the procedure was carried out in subdued light. Then transformation of cells was 
carried out in a Bio-Rad Gene-Pulser apparatus by mixing vector DNA and un-induced cells or 
SOS-induced cells. Cells were grown for 1 h at 37° C after adding SOC medium and then plated 
on a 1X YT plates containing Ampicillin and the transformants were analyzed by hybridization.  
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4. 3 Results and Discussion 
         The strategy for construction of the adduct containing single stranded vector was developed 
by Moriya84 and has used been successfully by our lab85–88 and many other researchers.89–91 We 
used pMS2 shuttle vector plasmid containing the origins of replication for f1, ColE1, and SV40, 
and the genes for neo and amp resistance.  
 
Figure 25. A general scheme for construction of the lesion-containing vector and replication in E. 
coli or HEK 293T cells, and analysis of the progeny 
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This single-stranded pMS2 vector also contain a hairpin region that, upon digestion with the 
EcoRV restriction enzyme followed by scaffolding with an oligonucleotide, generates the desired 
gapped duplex (Figure 25). The 15-mer oligodeoxynucleotide (5’-GCCCTCAA*CAAGATG-3’) 
containing N-(dA-8-yl)-6-AC adduct is ligated to this gap and the scaffold was enzymatically 
removed before replication. The strategy for construction and mutant screen assay is shown in 
Figure 25.   
Mutational analyses of N-(dA-8-yl)-6-AC in E. coli 
 
         The DNA sequence of the 15-mer was chosen from TP53 gene codon 129-133, because crops 
contaminated with another nitroaromatic carcinogen aristolochic acid (AA) causes A→T mutation 
in codon 131 in patients with urothelial tumors. While many polyaromatic amine and nitroaromatic 
compounds form adducts at the C8 position of dG, which induce frameshifts and G→T 
transversions as the dominant mutations, the major adducts by AA are formed at the N6 position 
of dA. The N-(dA-8-yl)-6-AC containing plasmid was replicated in uninduced and SOS-induced 
E. coli AB1157 cells. In uninduced cells, the number of progeny colonies from the adduct 
containing construct was reduced to ~60% to that of the control (Figure 26A). This suggests that 
though replication was inhibited, N-(dA-8-yl)-6-AC is less toxic than the C8 dG adduct of 1-
nitropyrene,8,78 which gives less than 30% progeny. Upon induction of SOS, viability of the 
adducted genome increased to nearly 90%, indicating significantly more facile translesion 
synthesis (TLS) of N-(dA-8-yl)-6-AC by the SOS proteins (Figure 26A). 
         Without SOS, 5.2% of the replicates were mutants, which comprised of 2.9% targeted and 
2.3% semi-targeted mutants (Figure 26B). Of the targeted mutations, 80% was A*→G transitions.  
With SOS, overall MF increased to 12.2%, showing three-fold increase of the targeted mutations 
to 9% frequency, whereas semi-targeted mutation increased only marginally to 3.2% (Figure 26C). 
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Although A*→G was also the prevalent (55%) targeted mutation with SOS, nearly half as many 
A*→C was detected.         
 
Figure 26. (A) The bypass efficiencies in N-(dA-8-yl)-6-AC construct in E. coli (-) SOS (WT) and 
(+) SOS cells. The data represent the means and standard errors of the mean of results from 3 
independent replication experiments. (B) The frequencies of total targeted mutations (C) induced 
in progeny from N-(dA-8-yl)-6-AC construct in (-) SOS (WT) and (+) SOS E. coli cells. The data 
represent the means and standard errors of the mean of results from 3 independent replication 
experiments. *P < 0.05; ***P < 0.001. The P-values were calculated by using unpaired two-tailed 
Student’s t-test.   
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Translesion Synthesis of N-(dA-8-yl)-6-AC in Human Cells  
         To investigate the replication properties of  N-(dA-8-yl)-6-AC adduct in human cells and the 
role of TLS polymerases in bypassing this lesion in cells; we conducted replication experiments 
in HEK293T cells and in HEK293T isogenic cells where individual TLS DNA polymerases were 
depleted by the CRISPR/Cas9 genome editing method and siRNA knock down approach.79,92  To 
study the role of specific TLS polymerase in the bypass of a lesion many researchers have 
conducted replication experiments in cells where specific TLS polymerase have been knockdown 
by siRNA approach.85,86 However, the siRNA method often results in incomplete depletion of TLS 
polymerases.  The presence of residual amounts of TLS Pols makes is difficult to draw clear 
conclusions about the role of specific polymerases in lesion bypass.92,93  The recent advances in 
CRISPR-Cas9 genome editing method has enabled the facile knockout of individual genes in 
cultured human cells .94,95 To determine the TLS efficiency of N-(dA-8-yl)-6-AC adduct in HEK 
293T cells, we mixed 3:1 ratio of N-(dA-8-yl)-6-AC vector and unmodified plasmid that contained 
a different unmodified sequence. The unmodified plasmid was used as an internal control. The 
percentages of the colonies originating from the N-(dA-8-yl)-6-AC lesion-containing construct 
relative to the unmodified plasmid, reflecting the percentage of TLS, were determined by 
oligonucleotide hybridization. 
         In contrast to TLS efficiency in E. coli WT cells which was 60%; TLS replication efficiency 
was 83% in HEK293T WT cells in which all TLS polymerases are expressed (Figure 27). The 
largest decrease in TLS efficiency was observed in Pol η KO cells (45%).  In Pol κ and Pol ζ KO 
cell TLS efficiencies were ~60 % and ~70 % respectively. TLS efficiency decreased only 
marginally in Pol ι KO cells. TLS efficiencies in Pol η/κ and Pol η /ζ double KO cells were ~25 % 
and ~35% respectively. In Pol ζ KO and Pol κ KD cells TLS efficiency was ~54%. On the basis 
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of TLS replication bypass efficiencies, the role of TLS Pols in the bypass of N-(dA-8-yl)-6-AC 
can be rank as follows Pol η > Pol κ > Pol ζ > Pol ι.  
 
 
Figure 27. TLS bypass efficiencies of the N-(dA-8-yl)-6-AC containing construct in HEK293T 
cells and various TLS polymerase KO HEK 293T cells. The data represent the means and standard 
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errors of the mean from 2-4 independent replication experiments. *P < 0.05; **P < 0.01; ***P < 
0.001. The P-values were calculated by using unpaired two-tailed Student’s t-test. 
 Mutational analyses of N-(dA-8-yl)-6-AC in Human Cells  
         DNA sequence analysis showed that N-(dA-8-yl)-6-AC is mutagenic in HEK293T cells. 
Replication of plasmid containing a single site-specific N-(dA-8-yl)-6-AC adduct in HEK293T 
wild type cells provided ~12 % progeny plasmid with mutations that included ~11% at the targeted 
site and ~ 1% occurred at the 3’ or 5’ end of the target site and are referred to as semi-targeted 
mutations (Figure 28).  In HEK293T wild type cells, mutations at the target site that were largely 
A→T transversions. We observed 4-fold decrease in mutation frequency when the plasmid is 
replicated in polymerases κ or ζ HEK293T individually KO cells. Similar experiments in 
polymerase η KO cells showed a 1.5-fold increase in mutation frequency. We also noted that 
plasmid replication in polymerases ζ KO and κ siRNA knock down cells resulted in 10-fold 
decrease in mutation frequency.  
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Figure 28. Targeted and semi-targeted mutations induced in the progeny from the N-(dA-8-yl)-6-
AC construct in HEK 293T and various polymerase knockout cells. The data represent the mean 
and the standard deviation (of the total MF) from 2-4 independent experiments. The statistical 
significance of the difference in MFs between HEK 293T and TLS pols knockouts was calculated 
using two-tailed, unpaired Student’s t test. (*P < 0.05; **P < 0.01; ***P < 0.001).  
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Figure 29. The types and frequencies of targeted mutations induced in the progeny from the N-
(dA-8-yl)-6-AC construct in HEK 293T cells and various polymerase knockout HEK293T cells. 
The data represent the mean and the standard deviation (of the total targeted MF) from 2-4 
independent experiments. The statistical significance of the difference in targeted MFs between 
HEK 293T and TLS pols knockouts was calculated using two-tailed, unpaired Student’s t test. (*P 
< 0.05; **p < 0.005).  
The Role of Specific TLS Polymerases in N-(dA-8-yl)-6-AC TLS Bypass  
         The results from TLS replication efficiency assay and DNA sequencing analysis (Figure 29) 
suggest that Pol η is strongly involved in bypassing N-(dA-8-yl)-6-AC DNA lesion in an error free 
manner.  Neither TLS bypass efficiency nor mutation frequency differed significant from the wild 
type results when N-(dA-8-yl)-6-AC vector was replicated Pol ι KO cells. This suggests that Pol ι 
does not play a significant role in bypass of N-(dA-8-yl)-6-AC DNA lesion.  We observed 4-fold 
decrease in mutation frequency when the plasmid is replicated in polymerases κ or ζ HEK293T 
KO cells. A*→ T transversions were the main mutation induced by N-(dA-8-yl)-6-AC adduct in 
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HEK293T cell. However, in Pol κ KO cells A*→ G transitions were induced at a higher frequency 
than A*→ T transversions. This suggests that Pol κ in responsible for inducing a significant 
amount of A*→ T transversions when N-(dA-8-yl)-6-AC vector is replicated in HEK293T cells. 
Furthermore, the decrease in mutation frequency in the absence of polymerases κ and ζ suggests 
that polymerases κ and ζ are strongly involve in the error-prone or mutagenic bypass of N-(dA-8-
yl)-6-AC. Replication experiments in cells where κ and ζ are simultaneously depleted resulted in 
10 fold decrease in mutation frequency suggesting that κ and ζ are cooperatively involved in the 
error-prone bypass of N-(dA-8-yl)-6-AC adduct.  
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4. 4 Conclusion 
         In conclusion, N-(dA-8-yl)-6-AC is mutagenic in E. coli and HEK293T cells.  In E. coli, N-
(dA-8-yl)-6-AC DNA adduct induces ~5 % mutant progeny in wild type cells. The induction of 
SOS response increases lesion bypass efficiency from ~60 % (wild type cells) to ~90% in SOS 
induced cells and increased targeted mutation in progeny 3-fold. This can be attributed to increase 
expression of low fidelity TLS polymerases pol II, pol IV and pol V. The major type of targeted 
mutation was A*→G in both uninduced and SOS-induced cells. In contrast, In HEK293T cells    
N-(dA-8-yl)-6-AC DNA adduct induces~12 % progeny plasmid with mutations largely A*→T 
transversions. In HEK293T cells, polymerases κ and ζ are cooperatively involved in the error-
prone bypass of N-(dA-8-yl)-6-AC adduct while pol η in strongly involved in the error-free bypass. 
Thus, our study provided important new insight into cellular replication properties of N-(dA-8-yl)-
6-AC lesion and defined the roles of TLS polymerases in bypassing this lesion in E. coli and human 
cells.  
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Chapter 5  
Mutagenicity and Genotoxicity of Fapy.dG DNA Adduct in Human Cells 
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5.  Abstract  
         Fapy·dG are formed in DNA by hydroxyl radical damage. In order to study replication bypass 
efficiency and mutation outcomes of Fapy.dG lesion in HEK293T cells, we constructed a single-
stranded shuttle vector containing the lesion. Two plasmid vectors containing Fapy.dG adduct at 
the G1- or G3-positions of a part p53 sequence, 5’-AAC CG1G AG3G CCC-3’ containing mutation 
hotspot codon 248 (red) or codon 249 (green). Replication of vectors in human embryonic kidney 
HEK293T cells, showed that Fapy.dG DNA adduct is mutagenic inducing largely G*→T 
transversions. Furthermore Fapy.dG adduct in CG*G sequence context (codon 248) induce 
mutations at ~50% greater frequency than AG*G in codon 249. The roles of several translesion 
synthesis (TLS) replication polymerases in adduct bypass was also investigated via conducting 
replication experiments in the isogenic cells where individual TLS DNA polymerases were 
depleted by the CRISPR/Cas9 genome editing method. Mutational analyses in HEK293T KO cells 
are in progress. 
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5. 1 Introduction  
         Oxidative DNA damage from reactive metabolites produced in cells can play important roles  
in aging and various diseases.96,97  Ionizing radiation generates many lesions in DNA that are 
formed by oxidative stress. It is now clear that oxidative DNA damage induces many different 
lesions in DNA, of these lesions 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) has received 
the most of attention.98 However, oxidative DNA damages also generates ring-opened 
formamidopyrimidine derivative, Fapy.dG. It is believed that 8-oxo-dG and Fapy.dG derives from 
a common radical intermediate (Scheme 8).99–102 
 
Scheme 6. Postulated hydroxyl radical mediated pathway to Fapy.dG and 8-oxo-dG 
 
        Fapy·dG DNA lesions is subject to repair by excision repair enzymes. Formamidopyrimidine 
glycosylase (fpg, MutM) is known to excise several oxidative damages such as Fapy.dG.101 The 
site-specific synthesis of Fapy.dG DNA adduct and incorporation in oligodeoxynucleotides have 
been accomplished.103,104 These advances in the synthesis of oligodeoxynucleotides containing 
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Fapy·dG have enabled biological studies that investigate biological endpoints of Fapy.dG in cells 
and the role TLS polymerases in bypassing Fapy.dG adduct in cells.105 Kalam et. al. showed that 
that Fapy·dG is mutagenic when the modified vector containing Fapy.dG is replicated in simian 
kidney (COS-7) cells, inducing primarily targeted Fapy·G→T transversions. In the 5’-TGT 
sequence mutational frequency of Fapy·dG was ~30%, whereas in the 5’-TGA sequence it was 
~8%.87 Using a similar approach, Pande et. al. reported that DNA polymerase λ is responsible for 
a significant portion of Fapy·dG induced G → T mutations in human cells, whereas it conducts 
predominantly error-free bypass of 8- oxo-dG.85  
 
Figure 30. Oligonucleotide sequences from the p53 hotspots that include codons 248 and 249 
 
         In contrast, this work aims at determining the mutational signatures of Fapy.dG in interesting 
p53 hotspots sequences that include codons 248 and 249. The mutations in p53 gene in cancer are distinct 
and have been noted in several hot spots such as at codons 157, 175, 248, 249, and 273, which correspond 
to amino acids within the DNA binding domain of p53.21,106,107 In human breast cancer, p53 codon 248 is 
most frequently mutated. Nearly 50% of all colon cancers contain mutations at the three CpG hot spots at 
codons 175, 248, and 273.107 By contrast, in hepatocellular carcinoma, G →T transversion of the second G 
in codon 249 occurs frequently, in which the mutated G appears in a GpG sequence. Indeed, GpG sequences 
are hot spots for oxidative damage.108 Furthermore, oxidative damage of human fibroblasts with H2O2 and 
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FeCl3 induced G:C →T:A transversions at p53 codons 249 109, which is also a susceptible site in DNA 
isolated from the liver tissues of Wilson’s disease patients.110   
5. 2 Material and Methods 
5. 2. 1 Synthesis of Fapy.dG containing oligonucleotides  
The synthesis and characterization of Fapy·dG 12mers, 5’-AAC CG*G AGG CCC-3’and 5’-AAC 
CGG AG*G CCC-3 were synthesized in the laboratory of Prof. Marc Greenberg and have been 
reported.36,98,104 The unmodified and complementary oligodeoxynucleotide sequences were 
purchased from Integrated DNA Technologies, Inc in Coralville, Iowa, USA.  
5. 2. 2. Single stranded vector construction and replication studies. 
Procedure for construction and characterization of pMS2 vectors containing a single Fapy·dG site 
are reported in section 4. 2. 2 of thesis.  
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5. 3 Results and Discussion  
         To investigate the mutation outcome of Fapy.dG in p53 hotspot sequences, single-stranded 
pMS2 vectors bearing a single Fapy.dG adducted site were constructed with different modified 
oligodeoxynucleotides. Modified vectors were constructed with 5’-AAC CG*G AGG CCC-3’ 
(dG1-Fapy) where codon 248 is underlined and with 5’-AAC CGG AG*G CCC-3 (dG3-Fapy) 
where mutation hotspot codon 249 is underlined. These adduct containing oligodeoxynucleotides 
and unmodified control oligodeoxynucleotides were inserted into plasmids to construct site-
specifically modified vectors using recombinant DNA technology. These vectors were replicated 
human embryonic kidney (HEK293T) cells. The resulting double stranded plasmid DNA was 
isolated and analyzed via oligonucleotide hybridization and DNA sequencing (Figure 30).  
 
 
Figure 31. Progeny plasmid processing via oligonucleotide hybridization and DNA sequencing 
 
         Oligonucleotide hybridization and DNA sequencing showed that Fapy.dG is mutagenic in 
HEK293T cells, inducing largely G*→T transversions. Furthermore Fapy.dG adduct in CG*G 
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249. TLS replication bypass efficiencies of the Fapy.dG containing vector in HEK293T cells were 
~90% and ~88% respectively for dG1-Fapy (codon 248) and dG3-Fapy (codon 249) sequences. 
Thus, bypass efficiency for Fapy.dG in G1 or G3 sequence were essentially the same in both 
sequence context.     
 
 
Figure 32. (A) The bypass efficiencies of Fapy.dG constructs (G1 and G3) in HEK293T cells. The 
data represent the means and standard errors of the mean of results from 3 independent replication 
experiments. (B) The frequencies of total targeted mutations induced in progeny from Fapy.dG 
construct in dG1-Fapy and dG3-Fapy. 
         DNA sequencing analysis showed that Fapy.dG in codon 248 induces ~12% mutant progeny 
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transversions at the target site.  In similar work from our lab, Pande et al. showed that 
Fapy.dG  induces 10−22% mutations, predominantly G → T transversions, in human embryonic 
kidney 293T cells in four TG*N sequence contexts, where N = C, G, A, or T.85 This current study 
aims at investigating and defining the mutation signature of Fapy.dG in p53 mutation hotspots 
sequences realized from cancer patients.  
5. 4 Conclusion  
          In conclusion, Fapy.dG is mutagenic in HEK293T cells inducing mainly G→T 
transversions. In the p53 sequence, the lesion is most mutagenic when located at G1 (codon 248). 
Nonetheless, Fapy.dG is also mutagenic when located at G3 position (codon 249).  
5. 5 Future Direction 
         The effect of specific TLS replication proteins in bypassing Fapy.dG lesion in codon 248 
and 249 p53 sequences will be assessed by performing TLS assay in CRISPR/Cas9 genome edited 
knockout human embryonic kidney cells (HEK293). TLS efficiency will be assessed with pol η, 
pol κ, pol ι, Rev 1 single knock out cells; followed by TLS assay in double/ triple knock out cells.  
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Figure S1. 1H NMR spectrum of 8-bromo-2’-deoxyadenosine  
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Figure S2. 13C NMR spectrum of 8-bromo-2’-deoxyadenosine  
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Figure S3. MS spectrum of 8-bromo-2’-deoxyadenosine  
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                                               m/z observed : 330.0188
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Figure S4.1H NMR spectrum of 8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (4) 
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Figure S5. MS spectrum of 8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (4) 
m/z calculated for C22H40BrN5O3Si2+: 558.67
                         m/z observed: 558. 1917
N
NN
N
NH2
O
TBDMS-O
Br
O-TBDMS
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Figure S6. 1H NMR spectrum of 8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (5)  
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Figure S7. 13C NMR of 8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (5)  
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Figure S8. MS spectrum of 8-bromo-3’, 5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (5)  
 +TOF MS: 0.032 to 0.082 min from Sample 1 (TuneSampleID) of 011816-Brent-Protected dG.wiff
a=3.60144582785556810e-004, t0=6.37966570470817090e+001 (Turbo Spray)
Max. 3200.8 counts.
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Figure S9. 1H NMR spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (6b) 
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Figure S10. 1H NMR spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (6b) 
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Figure S11. MS spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-N6-dimethoxytrityl-2’-deoxyadenosine (6b) 
     
6b 
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Figure S12. 1H NMR spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (6a)  
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Figure S13. 13C NMR spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (6a)  
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Figure S14. MS spectrum of 8N-(6-aminochrysene)-3’,5’-O-bis(tert-butyldimethylsilyl)-2’-deoxyadenosine (6a)  
 +TOF MS: 0.049 to 0.682 min from Sample 1 (TuneSampleID) of 060815-BVP-DMT-ClE.wiff
a=3.60041086922528760e-004, t0=6.27962639916586340e+001 (Turbo Spray)
Max. 1017.0 counts.
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Figure S15. 1H NMR spectrum of 8N-(6-aminochrysene)-2’-deoxyadenosine (3) 
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Figure S16. 13C NMR spectrum of 8N-(6-aminochrysene)-2’-deoxyadenosine (3) 
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Figure S17. 1H-1H ROESY NMR spectrum of 8N-(6-aminochrysene)-2’-deoxyadenosine (3) 
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Figure S18. MS spectrum of 8N-(6-aminochrysene)-2’-deoxyadenosine (3) 
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Figure S19. 1H spectrum of N6-Benzoyl-8N-(aminochrysene)-2'-deoxyadenosine (7) 
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Figure S20. 13C spectrum of N6-Benzoyl-8N-(aminochrysene)-2'-deoxyadenosine (7) 
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Figure S21. MS spectrum of N6-Benzoyl-8N-(aminochrysene)-2'-deoxyadenosine (7) 
 
 +TOF MS: 3.348 to 3.581 min from Sample 1 (TuneSampleID) of 061616-Brent-Ben-DPR-OH.wiff
a=3.60095417166520350e-004, t0=6.43268010587999020e+001 (Turbo Spray)
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Figure S22. MS spectrum of N6-Benzoyl-8N-(6-aminochrysene)-5'-O-dimethoxytrityl-2'-deoxyadenosine  
 
 +TOF MS: 1.332 to 1.615 min from Sample 1 (TuneSampleID) of 080216-Brent-5-DMTr.wiff
a=3.60083540110247080e-004, t0=6.44753197454556360e+001 (Turbo Spray)
Max. 6184.9 counts.
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Figure S23. 31P spectrum of N6-Benzoyl-8N-(6-aminochrysene)-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-
(cyanoethyl-N,N'-diisopropyl-phosphoramidite (8)  
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Figure S24. MS spectrum of N6-Benzoyl-8N-(6-aminochrysene)-5'-O-dimethoxytrityl-2'-deoxyadenosine-3'-O-
(cyanoethyl-N,N'-diisopropyl-phosphoramidite (8)  
 +TOF MS: 2.235 to 2.385 min from Sample 1 (TuneSampleID) of 101116-Brent-Phosphoramidile.wiff
a=3.60485127759944080e-004, t0=6.35676267610148930e+001 (Turbo Spray)
Max. 1.3e4 counts.
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Figure S25. ESI-MS (negative mode) spectrum of N-(dA-8-yl)-6-AC modified 12-mer oligodeoxynucleotide  
jlb20170614_BPowell_12mer2_1uM_1 #502-524 RT: 0.60-0.62 AV: 23 NL: 1.97E6
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Figure S26. ESI-MS (negative mode) spectrum of N-(dA-8-yl)-6-AC modified 15-mer oligodeoxynucleotide  
jlb20170614_BPowell_15mer_1uM_1 #578-602 RT: 0.68-0.71 AV: 25 NL: 1.09E6
T: FTMS - p ESI Full ms [333.4000-5000.0000]
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Figure S27. 20% PAGE Gel of Pure N-(dA-8-yl)-6-AC modified 12-mer and 15-mer oligodeoxynucleotides 
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Table S1. Mutational frequency in wild type (-) SOS and (+) SOS E. coli (AB1157) cells 
 
                                                                                                                                                                                                                                   
5’-G1C1C2 C3T1 C4A1 A*2C3A3A4G2ATG3-3’ 
Replication in E. coli Strain AB1157 
            
Exp # 
Total 
colonies 
screened 
Total 
no. of 
mutants 
             
MF (%) 
% 
Survival 
                                                                               
Targeted Mutations 
                       
Semi-Targeted Mutations 
[no. of mutants] (%)  
     A*→T 
(%) 
A*→G 
(%) 
A*→C 
(%) 
A*del 
(%) 
 
1 (-) SOS 149 9 6.0 65** 0 
-- 
4 
(2.68) 
0 
-- 
0 
-- 
5’-A1A*2C →TGC [4] (2.7) 
5’-G1C1C2→ GGC [1] (0.7) 
5’-A3A4G2→ _AG [4] (2.7) 
2 (-) SOS 98 3 3.0 62* 0 
-- 
2 
(2.04) 
0 
-- 
0 
-- 
5’-A1A*2C →TGC [2] (2.0) 
A3A4G2→ _AG [1] (1.0) 
3 (-) SOS 265 15 5.6 58*** 2 
(0.75) 
6 
(2.26) 
0 
-- 
0 
-- 
A1A*2C →TGC [2] (0.8) 
5’-G1C1C2→ GGC [1] (0.3) 
A*2C3A3A4G2ATG del. [3] (1.1) 
5’-C4A1 A*2 deletion [1] (0.8) 
C3 del [1] (0.3) 
 5’-A*2C3A3A4G2ATG [1] (0.3) 
 137 
4 (-) SOS 158 8 5.0 51* 1 
(0.6) 
4 
(2.53) 
0 
-- 
1 
(0.6) 
A1A*2C →TGC [1] (0.6) 
A1 or A*2 del [1] (0.6) 
(-) SOS 
TOTALS 
670 35 5.2% 
 
59 3 
(0.45%) 
16 
(2.4%) 
0 
-- 
1 
-- 
16 
(2.4%) 
1 
(+) SOS 
183 25 13.6 89*** 3 
(1.64) 
9 
(4.92) 
7 
(3.82) 
0 
-- 
G1→ C [1] (0.54) 
G3→ A [1] (0.54) 
G3 del [1] (0.54) 
C3T1 C4 → TT1A [1] (0.54) 
5’-C3T1 C4A1 del [2] (1.09) 
2 
(+) SOS 
127 13 10.23 85*** 2 
(1.57) 
7 
(5.51) 
1 
(0.78) 
0 
-- 
5’-C3A3A4 del [1] (0.79) 
T1 del [1] (0.79) 
C1→ A [1] (0.79) 
(+) SOS 
TOTALS 
310 38 12.2% 87 5 
(1.61) 
16 
(5.16) 
8 
(2.58) 
0 
-- 
10 
(3.2%) 
*3 Plates Average; **3 – 6 Plates Average; ***6 – 12 Plates Average 
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Table S2. TLS efficiencies and mutational frequencies in HEK WT and KO cells 
 
 
                                                                                                                                                                                                                                   
5’-G1C1C2C3T1C4A1 A*2C5A3A4G2A5TG-3’ 
Replication in HEK 293T WT cells  
Exp # # of 
Colonies 
Screened 
Mutants MF (%) % 
Survival 
Targeted Mutations Semi-Targeted Mutations 
[# of mutants] (%) 
     A*→T A*→G A*→C A* del  
1 
HEK293T 
88 15 17.0 --- 
 
6 5 1 0 C3 →T [1] (1.1) 
C1→ G [1] (1.1) 
T2 del [1] (1.1) 
2 
HEK293T 
289 36 12.4 87* 23 7 2 0 C3 →T [1] (1.1) 
C1→ G [1] (1.1) 
T2 del [1] (1.1) 
3 
HEK293T 
512 59 11.5 82** 38 14 2 0 A1 del [2] (0.4) 
A1→ T [1] (0.2) 
C5 →T [2] (0.4) 
4 
HEK293T 
257 25 9.7 79*** 13 8 1 0 A1 →T [2] (0.8) 
A1 del [1] (0.4) 
WT 
Totals 
 
1146 
 
135 
 
11.8% 
 
83% 
80 
[7.0%] 
34 
[2.96%] 
6 
[0.52%] 
0 14 
[1.22%] 
Replication in HEK 293T Pol K KO cells 
 139 
1 
Pol K KO 
376 15 4.0 --- 
 
4 5 2 0 A1→T [1] (0.6) 
C5 del [1] (0.6) 
A3A4G2 [2] (1.7) 
2 
Pol K 
KO 
489 13 2.7 62*** 3 8 0 0 T1C4 del [1] (0.2) 
C5 del [1] (0.2) 
3 
Pol K 
KO 
324 10 3.0 58** 1 6 1 0 A3A4 del [1] (0.3) 
A1→ T [1] (0.3) 
Pol K- 
Totals 
 
1189 
 
38 
 
3.2% 
 
60% 
8 
[0.7%] 
19 
[1.6%] 
3 
[0.25%] 
0 8 
[0.7%] 
Replication in HEK 293T Pol Z KO Cells 
1 
Pol Z 
KO 
266 10 3.8 70** 7 1 0 1 C5 → T [1] (0.4) 
2 
Pol Z 
KO 
197 8 4.0 73* 5 2 0 0 A1A2* del [1] (0.5) 
Pol Z- 
Totals 
 
463 
 
18 
 
3.88% 
 
71.5% 
12 
[2.6%] 
3 
[0.64%] 
0 1 
[0.2%] 
2 
0.4% 
Replication in HEK 293T Pol I KO Cells 
1 
Pol I 
218 24 11.2 77* 11 8 2 0 A1→ T [2] (0.9) 
C4A1 del [1] (0.5) 
 
 140 
KO 
2 
Pol I 
KO 
189 18 9.7 81* 9 6 0 0 C4A1A*2 del [1] (0.5) 
T1C4 del [1] (0.5) 
A1→ T [1] (0.5) 
3 
Pol I 
KO 
102 10 9.8 81* 4 3 1 0 A3A4 del [2] (0.3) 
 
Pol I- 
Totals 
 
509 
 
52 
 
10.2% 
 
80% 
24 
[4.7%] 
17 
[3.3%] 
3 
[0.6%] 
 8 
[1.6%] 
Replication in HEK 293T Pol H KO Cells 
1 
Pol H 
KO 
212 38 17.9 47*** 21 10 0 0 C2C3T1C4A1 A*2del [2] (0.9) 
C1→ G [1] (0.5) 
A1→ T [3] (1.4) 
C5 del [1] (0.5) 
2 
Pol H 
KO 
165 29 18.3 42** 15 8 0 0 C5 → T [2] (1.2) 
A1→ T [1] (0.6) 
C5 del [1] (0.6) 
Pol H- 
Totals 
 
377 
 
67 
 
17.7% 
 
45% 
36 
[9.5%] 
18 
[4.8%] 
0 0 13 
[3.4%] 
Replication in HEK 293T Pol H/Z DKO Cells 
 141 
1 
Pol H/Z 
KO 
278 13 4.8 32*** 10 1 0 0 A1→ T [1] (0.4)  
C5 del [1] (0.4) 
2 
Pol H/Z 
KO 
320 14 4.4 34*** 9 2 0 0 C5 → T [2] (0.6) 
A1 del [1] (0.3) 
 
3 
Pol H/Z 
450 18 4.0 36*** 14 2 0 0 C5 → T [2] (0.4) 
 
Pol H/Z- 
Totals 
1048 46 4.4% 35% 33 
[3.14%] 
5 
[0.48%] 
1 
[0.09%] 
0 7 
[0.66%] 
Replication in HEK 293T Pol H/K DKO Cells 
1 
Pol H/K 
240 11 4.7 27** 8 1 0 0 C4A1 del [2] (0.8) 
2 
Pol H/K 
 
290 
15 5.3 25** 12 0 0 0 C5 → T [1] (0.3) 
A1→ T [2] (0.3) 
 
3 
Pol H/K 
 
198 
10 5.0 25** 9 1 0 0  
Pol H/K- 728 36 5.0% 25.6% 29 
[3.98%] 
2 
[0.3%] 
0 0 5 
[0.7%] 
Replication in HEK 293T Pol K/Z KD Cells 
 142 
1 
Pol Z/K 
670 7 1.04 55** 5 1 0 0 C5 → T [1] (0.15) 
2 
Pol Z/K 
503 5 0.99 51*** 3 1 0 0 C4 del [1] (0.2) 
3 
Pol Z/K 
278 4 1.43 56** 4 0 0 0 0 
Pol Z/K 1451 16 1.1% 54 12 
[0.83] 
2 
[0.14] 
0 0 2 
[0.14] 
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5’-AAC CG1*G AG3*G CCC-3’ 
 
Exp # 
No. of 
colonies 
screened 
 
Mutants 
 
MF (%) 
%  
Survival 
 
Targeted Mutations 
Semi-Targeted Mutations 
[# of mutants]  
G1- Codon 248 
     G*→T G*→C G*→A G* del  
1 
HEK293T 
250 33 13.5 --- 
 
19 11 2 0 C2C3C4 del [1]  
  
2 
HEK293T 
210 18 8.57 92** 12 4 1 0 C1→ G [1] 
 
3 
HEK293T 
280 36 13.0 88** 22 9 3 0 A1A2 del [1] 
C1 del [1] 
 
 
WT 
Totals 
 
740 
 
87 
 
12 % 
 
90% 
53 
[7.1 %] 
24 
[3.2 %] 
6 
[0.8 %] 
0 4 
[0.54 %] 
G3- Codon 249 
 G*→T G*→C G*→A G* del  
1 
HEK293T 
 
212 13 6.1 --- 
 
9 3 0 0 AG3*G CCC del [1] 
2 
HEK293T 
260 14 5.3 85** 11 2 0 0 C5 del [1] 
 
 145 
3 
HEK293T 
330 19 5.9 90** 14 4 1 0  
WT 
Totals 
802 45 5.7 % 88% 34 
[4.2 %] 
9 
[1.1 %] 
1 
[0.124%] 
0 2 
[0.25%] 
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1 2 3 4 5
Fapy.dG PAGE Gel
1-p53 CT       5’-GTG CGT GTT TGT
2-p53 CT       5’-GTG CGT GTT TGT
3-HY2169-1  5’-AAC CXG AGG CCC
4-HY2169-2  5’-AAC CGG AXG CCC
5-HY2169-3  5’-GTG CXT GTT TGT
X = Fapy.dG
